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ABSTRACT OF THE DISSERTATION 
 
Identification of IL-40, a Novel B Cell–Associated Cytokine 
By 
 
Jovani Catalán-Dibene 
 
Doctor of Philosophy in Biomedical Sciences 
 
 University of California, Irvine, 2018 
 
Professor Albert Zlotnik, Chair 
 
We describe a novel B cell-associated cytokine, encoded by an uncharacterized gene 
(C17orf99), whose expression is induced in B cells upon activation. C17orf99 is only 
present in mammalian genomes, and it encodes a small (~27kDa) secreted protein 
unrelated to other cytokine families, suggesting a function in mammalian immune 
responses. Accordingly, C17orf99 expression is induced in the mammary gland upon the 
onset of lactation, and a C17orf99-/- mouse exhibits reduced levels of IgA in the serum, 
gut, feces, and lactating mammary gland. C17orf99-/- mice have smaller and fewer 
Peyer’s patches and lower numbers of IgA secreting cells. The microbiome of C17orf99-
/- mice exhibits altered composition, likely a consequence of the reduced levels of IgA in 
the gut. While naïve B cells can express C17orf99 upon activation, their production 
increases following culture with various cytokines, including IL4 and TGF-β, suggesting 
that differentiation can result in the expansion of C17orf99-producing B cells during some 
immune responses. Taken together, these observations indicate that C17orf99 encodes 
xvii 
 
a novel B cell-associated cytokine, which we have called Interleukin-40, that plays an 
important role in the development of humoral immune responses. Importantly, IL-40 is 
also expressed by human activated B cells and by several human B cell lymphomas. The 
latter observation suggests that it may play a role in the pathogenesis of certain human 
diseases.
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CHAPTER 1 
INTRODUCTION TO CYTOKINE AND B CELL BIOLOGY 
  
2 
 
1.1 CYTOKINES, THE MESSENGERS OF THE IMMUNE RESPONSE 
The main function of the immune system is to protect the body from foreign (infection, 
toxins, etc.) and domestic (autoimmune diseases, sterile inflammation, cancer, etc.) 
insults. The immune system carries its functions through highly specialized cells divided 
in two effector systems, the innate immune system and the adaptive system. The innate 
immune system is the first line of defense and can carry out its effector function without 
antigen presentation. It is composed of complement proteins, barrier tissues (epithelium) 
and hematopoietic cells (dendritic cells, monocytes, macrophages, neutrophils, 
basophils, eosinophils, natural killer cells, natural killer T cells and mast cells). The 
epithelium produces a wide variety of defenses and also represent a physical barrier to 
the outside world (1); while hematopoietic cells such as macrophages and neutrophils are 
regularly the first cells to respond to an invading pathogen and thus they are initiators of 
the second line of defense of the adaptive immune system that initiate the recruitment 
and activation of cells of the adaptive immune system, that get activated through antigen 
processing and presentation (2-4). The adaptive immune system, in contrast, needs 
antigen presentation and “training” to develop a highly specific and potent immune 
response (3) and it is comprised of T and B lymphocytes. T cells are responsible for 
cytotoxic activity specialized in eliminating intracellular infections, as well as directing the 
immune response as T helper (Th) cells (5, 6); B cells (which can develop into plasma 
cells) are responsible for the production of antibodies and are paramount for the 
development of long lasting immunity (7). Together, they confer immune memory in 
response to specific antigens, a hallmark of adaptive immunity (8). The development and 
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control of all the phases necessary for mounting innate and adaptive immune responses 
include cells of each of these systems but they are all regulated by cytokines (9-11). 
Cytokines are small secreted proteins produced by cells of the immune system, usually 
upon cell activation. Cytokines are orchestrators of immune responses, since they 
coordinate the inflammatory response by inducing maturation, polarization, proliferation, 
survival and trafficking of immune cells (Figure 1) (12). They accomplish these tasks by 
activating specific gene expression pathways in responding cells (13). The regulation of 
gene expression by cytokines is complex and often involves checkpoints and multiple 
steps to ensure that the right immune response is elicited (14). From the evolutionary 
perspective, cytokines evolved from superfamilies that include interleukins (IL), colony-
stimulating factors (CSF), interferons (IFN), transforming growth factors (TGF), Tumor 
Necrosis Factors (TNF) and chemokines; many of these exhibit overlapping, synergic or 
antagonistic functions. 
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Figure 1.1. Role of cytokines in the regulation of the immune system. Cytokines can 
induce immune cells to polarize into effector cells that defend the body against pathogens 
(Inflammation) or to suppress inflammation and/or induce tolerance (Immune 
regulation). They also play an important role in tissue homeostasis by controlling 
trafficking of immune and somatic cells to other tissues and the maintenance of 
hematopoiesis (Tissue homeostasis). 
 
It is often overlooked that “simple” lifeforms such as flies (class Insecta) and early 
vertebrates such as jawless fish (class Agnata) are already capable of mounting effective 
immune responses (15-17). Pluricellular Protista and Invertebrates were the first 
organisms capable of mounting innate immune responses (around 542 million years ago), 
while the earliest adaptive immune responses first appeared in jawless fish (around 500 
million year ago) and has continued its evolution to date (Figure 2) (17). Cytokines were 
needed to manage these newly acquired defensive abilities, so as the defensive 
capabilities of organisms grew, the diversity of cytokines also grew. The evolutionary 
conservation of these cytokines is such that several mammalian cytokines are capable to 
elicit immune responses in worms, mollusk and insects. While Fish express ortholog 
cytokines of IL-1, IL-6, IL-17A, IL-10, IL-21 and TGF-β (17, 18). There is evidence that 
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cytokines evolved from intracellular proteins in invertebrates, which can only mount innate 
immune responses (10). Early cytokines acted mainly as transcription factors, an example 
of this is IL-33 (19). The diversity and functions of cytokines evolved as evolutionary 
pressure on pluricellular organisms by microorganisms, parasites and viruses grew. 
Additionally, the evolving organisms needed to control its own newly developed weapons 
turning against itself, further promoting diversification of immune components. In general, 
most gene families arose through evolution from an original ancestral gene through gene 
duplication and the resulting offspring genes then specialized, giving rise to a family of 
genes that encode structurally related proteins that developed specialized functions (20). 
The chemokines are an excellent example of this process, but it also applies to other 
cytokine families. Among the interleukins, IL-2 is evolutionarily related to IL-15 and to IL-
21, while IL-4 and IL-13 are the result of a gene duplication (indeed, their genes are still 
located adjacent to each other in the human genome) (16). There are several genes of 
the IL-10 family, but some of the largest interleukin superfamilies include IL-1 and IL-12, 
with several members each (16). In fact, among the latest discovered interleukins (IL-30 
to IL-40) there are several IL-1 superfamily members (IL-33, IL-36, IL-37, and IL-38) as 
well as several new members of the IL-12 family (IL-30, IL-35, and IL-39). 
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Figure 1.2. Evolution of the immune system. The inner painting shows representative 
animals of different organisms of the animal kingdom (Animalia). The rounded square 
shows the immune mechanism and the brackets indicate the animal groups where a 
specific immune mechanism evolved. Years are presented in million years (mya). The 
outer squares show the approximate geological period where the immune mechanisms 
appeared. First published in (17). 
 
1.2 CYTOKINES AND B CELL BIOLOGY 
B cells are the effector cells responsible for immunoglobulin (Ig) secretion in the organism, 
and thus the main drivers of the humoral immunity, a function of the adaptive immune 
response (21). They develop and mature in the bone marrow (BM) and continue their 
development and polarization in the periphery. These processes are tightly regulated by 
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cytokines (22). B cells develop from hematopoietic stem cells (HSCs) present in the bone 
marrow (23) that become committed to the B cell lineage. In the case of B cells, IL-7 
drives HSC differentiation to the B cell lineage and is produced by specialized stromal 
cells in the BM (24, 25). In fact, IL-7 receptor (IL-7R) is specifically expressed by early 
stages of B cell precursors in the bone marrow (26). TGF-β also plays a role in early B 
cell development by inhibiting the expression of IL-7 by stromal cells and by directly 
inhibiting the proliferation of Progenitor and Precursor-B cells (Pro- and Pre-B cell 
respectively) (27, 28). The maturation stages of B cells in the BM are marked by the 
rearrangement of the V, D and J immunoglobulin segments of the heavy chain and the V 
and J segments of the light chain of the B cell receptor (BCR) culminating in a fully 
functional IgM BCR (22). Once the BCR is formed the Immature B cell exits the BM and 
continues maturation in the germinal centers of the spleen or lymph nodes. Immature B 
cells are able to switch Ig class depending on the cytokines present in the 
microenvironment and help from CD4+ T helper cells. (29, 30). An immature B cell is 
capable of class switching to any of the known antibody classes: IgM, IgG1, IgG2a, IgG2b, 
IgG3 IgA and IgE. Each of these immunoglobulin classes has different functions (31). 
Outside of the BM, cytokines play a role in B cell activation, survival and antibody class 
switch recombination (CSR). IL-4 is one of the most important cytokines. IL-4 was first 
described as B cell growth factor and plays a role in the secretion of IgG1 and IgE (32, 
33) . IL-4 is produced by Th2 cells and it is necessary for effective B cell proliferation and 
survival (34). IL-6 is another important pro-inflammatory cytokine. It was originally named 
B cell stimulation factor 2, because it is capable of increasing the secretion of IgM and 
IgG (35). IFNγ, another cytokine found in the periphery, was originally described as an 
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antiviral cytokine, but it has a variety of other functions including the ability to regulate 
antibody production of immunoglobulins by B cells, inhibiting the production IgM, IgG1 
and IgE but inducing the secretion of IgG2a and IgG3 (which can neutralize viruses) (31, 
36). Finally, TGF-β induces CSR to IgA while inhibiting the induction of IgM, IgG2a, IgG3 
(37). Table I summarizes the effect of several cytokines in CSR and their ability to 
promote production of the different antibody classes.  
After B cells encounter the required signals to become a fully mature B cell it has three 
possible fates: 1) release antibodies and cytokines and die after losing the ability to 
respond to survival signals and cytokines; 2) following successful clonal selection 
(positive selection), B cells producing high affinity antibodies are selected to keep dividing 
and become long lived memory B cells; 3) B cells with the highest affinity for antigens will 
develop into long lived plasma cells (LPCs). These processes occur in the germinal 
centers of the spleen and lymph nodes (38-40). All these cells can produce cytokines to 
further improve and regulate immune responses (41, 42). 
Table I. Influence of cytokines in class switch recombination 
 Inmunoglobulin class 
Cytokine IgM IgG3 IgG1 IgG2b IgG2a IgA IgE 
Il-4 Inhibits Inhibits Induces  Inhibits   Induces 
IL-5           Enhances   
IL-6 Induces             
IFNγ Inhibits Induces Inhibits   Induces   Inhibits 
TGF-β Inhibits   Inhibits Induces   Induces   
 
B cells as cytokine producers  
As discussed above, B cells are mostly thought of as antibody secreting cells and for 
many years B cell research was shaped by this notion. However, since the late 2000s 
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thanks to the disseminated use of Rituximab, an anti-human CD20 monoclonal antibody 
(mAB) developed for the treatment of non-Hodgkin lymphoma, there is a growing body of 
evidence that points to a role of B cells in autoimmunity that is independent of their ability 
to produce antibodies (43, 44). Rituximab is a chimeric antibody that targets CD20 
expressing cells. In the B cell lineage, CD20 is expressed as early as the late Pro-B cell 
stages up until the memory B cell stage (45). Administration of Rituximab in vivo therefore 
leads to severe depletion of most CD-20-expressing B cells. In autoimmune disease, 
Rituximab was first tested in rheumatoid arthritis (RA) patients because RA pathology is 
characterized by the presence of activated B cells in the inflamed synovium as well as 
circulating autoantibodies that target multiple self-antigens (46). Rituximab was shown to 
have a dramatic beneficial effect in the resolution of RA, especially in combination with 
methotrexate (47, 48). Surprisingly, elimination of B cells does not cause autoantibody 
secretion to disappear (because LPCs do not express CD20). This was also true for 
systemic lupus erythematosus (SLE) patients treated with Rituximab (49, 50). These 
observations lead to the conclusion that the therapeutic effect of B cell depletion observed 
in RA patients must be mediated by antibody independent effector functions carried by B 
cells.  
In parallel to these observations, in recent years it has become clear that B cells are 
capable of secreting significant quantities of some cytokines (51). Lymphotoxin-α (LTα) 
and TNF-α produced by B cells play an important role in the organization of the germinal 
center in lymph nodes and the spleen (52, 53). In RA, activated B cells have been found 
to form active lymphoid ectopic structures in non-lymphoid tissues driven by LTα and 
TNF-α (54). These ectopic lymphoid structures are capable of presenting autoantigens to 
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T cells and induce pathogenic T cell activation (54). Recently a possible mechanism for 
Rituximab therapy in multiple sclerosis (MS) has been proposed. Li and collaborators 
identified a B cell subpopulation in MS patients capable of secreting GM-CSF, which in 
turn can activate pathogenic macrophages in vitro (55).  
The most researched B cell subpopulation with cytokine driven functions are B regulatory 
cells (Bregs). The role of B cells as immune suppressive cells was discovered by Wolf 
and collaborators when exploring the role of B cells in experimental autoimmune 
encephalomyelitis (EAE), a murine model of MS (56). In this study, they found that B cell 
deficient B10.PL (I-Au) mice have greater variation in disease onset, disease severity and 
are unable to recover from EAE pathology (56). Later the expression and secretion of IL-
10 by B cells was reported in colitis, EAE and RA, were they play a central role (57-59). 
Bregs are capable of secreting TGF-β and IL-10 when their BCR engages autoantigens 
(58). Interestingly plasma cells are also capable of producing IL-10 and another newly 
discovered anti-inflammatory cytokine, IL-35 (60). IL-10 and TGF-β work by 
downregulating the expression of pro-inflammatory cytokines which in turn is mediated 
by inhibition of the pro-inflammatory transcription nuclear factor κB (NF-κB) or 
antagonizing it in the case of TGF-β (61, 62). 
In fact, B cells (like T cells) require polarization with activating agents and cytokines in 
order to become active cytokine producers. Given the characteristics of activated B cells, 
Lund and collaborators coined the term effector B cell (Be cells) (51). B cells can also be 
primed for Type 1 (pro-inflammatory) and Type 2 (humoral) responses and called them 
Be1 and Be2 cells respectively to mirror Type 1 (Th1) and Type 2 (Th2) helper CD4+ T 
cell subsets (42). Not surprisingly, Be1 and Be2 can be found under the same 
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inflammatory environments that their T cell equivalents, Be1/Th1 in infections that induce 
Type 1 responses and Be2/Th2 in infections that induce Type 2 responses (Figure 3) 
(63).
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2
 
 
Figure 1.3. B effector cell polarization. B cells can secrete cytokines in response to T cell help and cytokine stimulation. B 
cells can be polarized into B effector 1 cells (Be1) which mirror Type 1 T-helper cells, B effector cells 2 (Be2) which mirror 
Type 2 T-helper cells 2 and B regulatory cells (Breg) which mirror T regulatory cells. 
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1.3 CYTOKINES IN DISEASE AND THERAPY 
Due to the pivotal role that cytokines play during inflammation it was evident that they are 
perfect targets for developing blocking or administration therapies. Surprisingly, there are 
not many treatments available involving cytokines. This could be due to the complexity of 
cytokine regulation. Many cytokines are pleiotropic, meaning that they can elicit different 
responses in different cells, sometimes even antagonistic. A good example of this is IL-
6, which can elicit pro-inflammatory and anti-inflammatory responses depending on the 
signaling mechanism used, membrane bound IL-6 receptor or soluble IL-6R (sIL-6R). 
Only few cells express the membrane bound receptor which triggers anti-inflammatory 
responses. Conversely, all cells express gp130 a membrane protein that interacts with 
sIL-6R to initiate a pro-inflammatory response (64). This complexity represents a 
challenge in developing effective cytokine-centered therapies. With the discovery of IFNs 
and their effects in vitro on viral infected cells and immune cell stimulation it was believed 
that they would be the perfect antiviral drugs (65), nevertheless they never proved 
effective for those purposes in humans (66). Given the processes that cytokines can 
regulate, uncontrolled expression of certain cytokines can lead to autoimmune disease 
and cancer (67). It is in these pathologies that cytokine-based therapies have proven most 
effective (67, 68). 
Interleukin 1 
In autoimmune diseases, pro-inflammatory, anti-inflammatory cytokines and chemokines 
play important roles. IL-1 family members represent mostly pro-inflammatory cytokines; 
in combination with other inflammatory cytokines, such as TNF-α and IL-6, induce 
cartilage destruction in RA (67, 69). IL-1β is upregulated in patients with RA compared 
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with patients that are on remission. It is also known to promote the activity of proteolytic 
enzymes that drive the destruction of cartilage in the joints (70, 71). Furthermore, IL-1 
also induces autoimmune attacks on β cells by T cells in type 1 diabetes (T1D) and it has 
also been shown that the NLRP3 inflammasome (which activates inactive intracellular IL-
1β) is upregulated in type 2 diabetes (T2D), contributing to β cell death and scaling 
inflammation in the pancreas (72, 73). Furthermore, IL-1β has been implicated in uveitis, 
pericarditis, gout, Sjögren’s syndrome, and interstitial lung disease, among others (70, 
74-77). In some of these cases IL-1β blocking therapies have proven successful (70). 
The most common treatment to date is the use of Anakinra (brand name Kineret) a 
recombinant human IL-1 receptor antagonist (IL-1RA), marketed by Swedish Orphan 
Biovitrium AB pharmaceutical. Anakinra has proven moderately effective in the treatment 
of RA as a second line of treatment or in combination with other drugs such as 
methotrexate (78-80). Canakinumab (brand name Ilaris) developed by Novartis is an anti-
human IL-1β mAB originally intended for the treatment of RA, but its effectiveness has 
been marginal (81, 82). Recently it has been approved for three rare autoimmune 
diseases Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), 
Hyperimmunoglobulin D syndrome (HIDS) and Familial Mediterranean Fever (FMF); IL-
1β (83-85). 
Tumor necrosis factor α 
TNF-α, a dual pro-inflammatory/anti-inflammatory cytokine, is one of the most prominent 
cytokines in autoinflammatory diseases (86). TNF-α is produced first as membrane bound 
cytokine and is released after cleavage by a TNF-α converting enzyme (TACE). Both 
forms signal through two receptors with different affinities and effects (87). Due to TNF-
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α’s effect on mucosal epithelia permeability, it has a prominent role in the pathogenesis 
of Crohn’s disease (CD) and ulcerative colitis (UC) (88, 89). It has also been found to 
participate in the pathogenesis of SLE, where surprisingly, patients undergoing TNF-α 
blockade for RA can develop autoimmune pathologies such as the production of 
antinuclear antibodies (ANAs), anti-double stranded DNA (dsDNA) and anticardiolipin 
antibodies (ACL) that can lead to SLE (90). In the context of SLE, TNF-α decreases the 
autoantigen presentation derived of apoptosis by acting directly on B cells as an inhibitor 
(activated B cells are also capable of TNF-α production); while at the same time inducing 
tissue destruction via apoptosis and immune cell activation (91-93). This is echoed in 
T1D, where TNF-α has a dual role, preventing the induction of autoantibodies that attack 
β cells and promoting inflammation at the same time (94, 95). Furthermore, some patients 
undergoing TNF blockade treatment for autoimmune diseases such as ankylosing 
spondylitis (AS), RA, psoriasis and CD and UC can show signs of demyelination in the 
central nervous system (CNS) a hallmark of MS (96, 97). In fact, the use of TNF-α 
blockade in MS proved to be counterproductive in humans by exacerbating the 
inflammation in the CNS (98). 
Adalimumab (trade name Humira) and Infliximab (trade name Remicade), developed and 
marketed by AbbVie Inc. and Johnson & Johnson respectively, are the most commonly 
used anti-TNF-α mAB in the world (99) designed to block TNFa effects in vivo. In fact, 
Adalimumab was the number one of the top selling drugs in the world until 2016 (when 
its US patent expired) with Infliximab in 5th position (100). Both mABs are prescribed for 
RA, psoriathic arthritis (PA), AS, CD, UC, psoriasis, hidradenitis suppurativa (HS) and 
juvenile idiopathic arthritis (JIA) alone or in combination with drugs such as methotrexate, 
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in the case of RA it doubles the patient response rate of methotrexate (101). These mAbs 
therefore represent some of the most successful drugs for treatment of autoimmune 
diseases and underscore the pivotal role that TNFa plays in these diseases. Ironically, 
their exact mechanism of action in these diseases is not well understood, even though 
they are very effective and widely used. 
Interleukin 17A 
IL-17A is pro-inflammatory cytokine discovered in 1993 by Rouvier and collaborators 
(102). IL-17A signals through IL-17 receptor (IL-17R), which is comprised of subunits IL-
17RA, IL-17RB, IL-17RC, IL-17D and IL-17E (103). IL-17 was one of the first cytokines 
to break the Th1/Th2 paradigm set by Mosmann and Coffman in 1989 (104) and 
consolidated a new cell linage that produces high quantities of IL-17 but no IFNγ or IL-4 
(Th1 and Th2 cytokines resplectively), named Th17 cells (105). IL-17 is important for the 
defense against extracellular pathogens such as Fungi through the recruitment and 
activation of neutrophils (82, 106, 107). Also, IL-17A expression synergizes with TNF-α 
and IL-1 and plays a particularly important role in barrier tissues, many epithelial cell 
express IL-17R (108, 109). IL-17 stimulation of epithelial cells leads to upregulation of IL-
6, TNF-α, CXCL8 and matrix metalloproteases (108, 110). Upregulation of IL-17A in 
several autoimmune diseases was quickly reported in disease such as psoriasis, RA, MS 
(111) and inflammatory bowel disease (IBD) (112-114). Blocking therapy for IL-17 was 
quickly developed in the early 2000s. The first anti IL-17A blocking antibodies were 
developed soon after the upregulation of IL-22 and IL-23 was discovered in several 
autoimmune diseases which are produced by Th17 cells (115-117). One of the first 
blocking antibodies developed and published with exceptional results in the treatment of 
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RA, psoriasis and uveitis (UV) was AIN457 later branded as secukinumab (trade name 
Cosentyx) by Novartis. Secukinumab is a fully human mAB antibody targeting IL-17A 
(118). As of 2018 it has been approved by the US Food and Drug Administration (FDA) 
for the treatment of plaque psoriasis, PA, and AS (118). Secukinumab is very effective in 
the treatment of all spectrums of severity in psoriasis, inducing rapid reduction (~4 weeks) 
of 50-75% of the psoriasis area and severity index (PASI) with some of the patients 
achieving PASI scores of 90-100%, outperforming anti-IL-23 mAB Ustekinumab 
(Centocor/Janssen biotech) (118, 119). IL-17A blockade provokes susceptibility to upper 
respiratory tract infections, nevertheless the adverse effects measured after 3 years of 
treatment are comparable to alternative treatments but with a significant increase in 
quality of life (118, 120). 
Interleukin 6 
IL-6 is a pleiotropic cytokine with pro-inflammatory and anti-inflammatory properties. As 
mentioned before, IL-6R can be expressed in two forms soluble and membrane bound. 
In both cases IL-6 signaling requires gp130 coreceptor to signal, but gp130 is capable of 
interact with soluble IL-6/IL-6R complex by itself (121). While membrane bound IL-6R is 
only expressed in hepatocytes, monocytes, macrophages and lymphocytes, the 
expression of gp130 is expressed in all cells, eliciting different responses depending on 
the signaling pathway engaged (121). IL-6 is a potent mediator of inflammation and IgG 
humoral responses (122, 123). Also, IL-6 acts directly on hepatocytes and is an activator 
of the acute phase response in the liver and thus is one of the main drivers of cytokine 
release syndrome (CRS) (124, 125). CRS is the most prominent adverse outcome of the 
newly developed Chimeric Antigen Receptor T cell (CAR-T cell) therapy for cancer (126, 
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127). CAR-T cells are genetically engineered to express specific T cell receptors (TCRs) 
with high specificity to tumor antigens (128).Tociluzimab (trade name Actemra), a mAB 
that targets IL-6, is very effective in the treatment of CRS (126, 127, 129, 130). Developed 
by Hoffman-La Roche/Chugai pharmaceutical company was initially developed for 
Castleman’s disease and JIA, both characterized by the upregulation of IL-6 (131). 
Although tociluzimab is approved by the FDA for RA, JIA and Castleman’s disease its 
use has been more effective in the treatment of CRS and has found a niche use in 
combination with CAR-T cell therapies. 
Colony stimulation factors 
CSFs are cytokines responsible of hematopoiesis in the bone marrow. Among CSFs 
erythropoietin and granulocyte colony stimulation factor (G-CSF) are the most used 
hematopoietic cytokines for the treatment of disease (66). They are particular in their 
clinical application in that they are among the only cytokines that are administered (via 
injection) as exogenous recombinant cytokines and are synthetized in vitro (132-134). 
Erythropoietin is marketed as Epoietin (trade name Epogen), developed by Amgen and 
used for the treatment of anemia provoked by chronic renal failure and cancer 
chemotherapy (132, 135). G-CSF is used to treat febrile neutropenia caused by 
myelosuppressive chemotherapy that leads to a myriad of complication such as infection 
susceptibility (136). The most popular recombinant G-CSF is Filgrastim (trade name 
Neupogen) also developed by Amgen and it is used to combat neutropenia caused by 
chemotherapy or induced neutropenia due to organ transplantation (134, 137). 
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Future directions in cytokine therapy 
The development of successful therapies that target cytokines has increased the interest 
in the discovery and functional characterization of novel cytokines and their potential role 
in human disease. In this section we reviewed the most successfully targeted cytokines 
that have led to new treatments for cytokine-driven pathologies (summarized in Table II). 
Given the intricate regulation of cytokines, harnessing their functions could be 
problematic. Nevertheless, various therapies have proven very successful, especially, in 
the treatment of autoimmune disease where novel biologics that target several cytokines 
have been developed. These successes have led to wide interest on the identification of 
novel cytokine targets. As a result, there are many new cytokines whose biology is a 
developing story. We will review some of these novel cytokines in this section and we will 
also predict that there are still some cytokines left to discover, a subject that we will touch 
on the next section. 
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Table II. Cytokine related drugs developed and approved for clinical use. 
Drug Trade name Type Target Diseases (FDA approved) 
Anakinra Kineret 
Recombinant  
IL-1RA 
IL-1β 
Rheumatoid arthritis (RA), Cryopirin-Associated 
Periodic Syndrome/Neonatal Onset Multisystem 
Inflammatory Disease (CAPS/NOMID) 
Canakinumab Ilaris mAB IL-1β 
CAPS, Tumor Necrosis Factor Receptor Associated 
Periodic Syndrome (TRAPS), Hyperimmunoglobulin D 
syndrome (HIDS) and Familial Mediterranean Fever 
(FMF) 
Adalimumab Humira mAB TNF-α 
RA, psoriasis, psoriatic arthritis (PA), ankylosing 
spondylitis (AS), Crohn's disease (CD), ulcerative colitis 
(CD), hidradenitis suppurativa (HS), juvenile idiopathic 
arthritis (JIA)  
Infliximab Remicade mAB TNF-α RA, psoriasis, PA, AS, CD, HS, JIA  
Secukinumab Cosentyx mAB IL-17A Psoriasis, PA, AS 
Ustekinumab Stelara mAB IL-23 Psoriasis, PA 
Tociluzimab Actemra mAB IL-6 
Cytokine release syndrome (CSR), Castleman's disease, 
RA, JIA 
Epoietin Epogen 
Recombinant 
Erythropoietin 
Megakaryocytes-
erythroid progenitor 
cells 
Anemia  
Filgrastim Neupogen 
Recombinant  
G-CSF 
HSCs Neutropenia 
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1.4 INTERLEUKIN 30-40 
The search for new cytokines  
From a functional standpoint, the first mention of cytokines as effector molecules came 
from ancient philosophers who wrote about “factors” existing in pus that led to fever, 
swelling and the production of more pus (10). It was until the 1970s when the first soluble 
factor with a specific immune function was described by Gery and Waksman (138), by 
stimulating splenocytes and thymocytes with phytohemagglutinin (PHA), concanavalin A 
(Con A) or lipopolysaccharide (LPS) and using “active” supernatants to stimulate 
proliferation of lymphocytes(138). They named the factor “lymphocyte activating factor” 
(LAF) and later was purified and characterized as “T cell growth factor” by Mier and Gallo 
(138, 139).  
The original cytokines were named “Interleukin 1” and “Interleukin 2”, which received their 
interleukin designation at the Second International Lymphokine Conference that was held 
in Interlaken, Switzerland in 1979. Since then, the number of interleukins has grown 
significantly. However, even though they are molecules of extreme importance in 
immunology, their numbers have made it difficult even for immunologists to keep pace 
with the discovery and characterization of these cytokines. Indeed, among them, there 
are some that have become ‘superstars’ of immunology (for example, IL17A), while others 
languish in relative obscurity (IL-11) as judged by the number of scientific papers 
documenting studies with these cytokines. By the onset of the XXI century, the number 
of interleukins reached IL-30 and has kept on increasing. There are currently 40 
interleukins named. Consequently, the last 10 are among the ones least studied.  
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The growing use of gene arrays and other gene expression analysis methods have also 
helped expand the universe of interleukins. A certain interleukin may become ‘popular’ 
through key studies published in the literature, but gene expression studies do not depend 
on the ‘popularity’ of a particular cytokine. They will faithfully reflect the levels of 
expression of a particular transcript in a given cell/tissue independently of its popularity in 
the literature. We expect that many of the interleukins we discuss in this review will show 
up in gene array studies which will help understand their functions and become better 
known. Personally, we found this exercise revealing, as it became clear that several of 
these molecules exhibit very interesting functions which strongly suggest that they may 
be important potential targets for future therapeutics. In fact, anti-cytokine (or anti-
cytokine receptor) antibodies already represent important therapeutics (anti-TNF-α, anti-
IL17A, anti-IL-23).  
The human genome contains an estimated 10% of genes encoding secreted proteins, so 
we can assume that there may be several new cytokines which are yet to be identified. 
Within the IL-30 to IL-40 cohort, some of them do not share homology with other cytokine 
families, these are represented by IL-31, IL-32, IL-34 and IL-40. These latter interleukins 
are generally more difficult to identify (because they do not share structural/genetic 
similarities to other cytokines) so they were generally identified through screening of 
genomic databases or other bioinformatics-based screening methods. 
Interestingly, the discovery of a new cytokine used to be a highly significant event in 
immunology. However, several of the novel cytokines described herein have not received 
significant attention when they were first reported. This is likely due to a phenomenon of 
‘interleukin fatigue’, that is, a belief that cytokine biology is mostly a done deal and not an 
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‘up and coming’ topic in immunology. This may be related to the fact that most cytokines 
were discovered by an older generation of immunologists, and cytokine discovery and 
characterization is not a very popular topic among young investigators. Another problem 
is that even when a new cytokine is discovered, there are no reagents available. This 
situation underscores the difficulty of studying the biology of new interleukins. However, 
despite these difficulties, it is apparent that the discovery of these new interleukins will 
open many new fields of research based on their very interesting biology and new 
potential targets for therapy. In this section I would like to summarize the finding and 
characteristics of the latest cytokines described.  
Interleukin 30 
IL-30, represented by the p28 subunit of IL-27, is part of the IL-12 cytokine family. IL-27, 
discovered by Pflanz et al (140), is a heterodimer composed of Epstein- Barr virus (EBV)-
induced gene 3 (Ebi3) subunit non-covalently associated with the smaller p28 subunit (IL-
27p28) (140). IL-30, the p28 subunit of IL-27, remains functional even in the absence of 
Ebi3 (141-143). Interleukin 12 family cytokines have emerged as critical regulators of 
immunity that regulate both pro-inflammatory (IL-12 and IL-23) and anti-inflammatory (IL-
27, IL-35, and IL-39) immune cell responses through their influence on T and B cell fates. 
The IL-12 family is unique in having the only heterodimeric cytokines, this promiscuous 
pairing of alpha and beta chains is speculated to contribute to the dual role of 
inflammatory and anti-inflammatory cytokines (144).  
IL-27 was initially thought to be a pro-inflammatory cytokine (145), but is now considered 
an immunoregulatory cytokine (146-148). IL-27 is secreted by activated antigen-
presenting cells such as macrophages and dendritic cells (140, 149). Toll-like receptor 
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(TLR) agonists such as LPS or CpG oligodeoxynucleotides and IFNα treatment of murine 
and human monocytes results in the production of IL-30. Once secreted, IL-27 binds to 
IL-27R alpha and the T cell cytokine receptor signaling through WSX-1 subunits and 
gp130 protein to include signal transducer and activator of transcription 1 (STAT1) and 
STAT3 in monocytes (149, 150). Recent studies have suggested that IL-30 may also 
signal through WSX-1 and gp130, but it may require a binding partner such as cytokine-
like factor (CLF-1) or soluble IL-6 receptor (sIL-6Ra) (141, 143, 151). 
Much more information is known about IL-27 than IL-30, however, they have been 
suggested to share overlapping roles. IL-27 has been shown to play an anti-inflammatory 
role in models of autoimmunity such as autoimmune encephalomyelitis and collagen-
induced arthritis (152, 153). IL-27 downregulates the immune response by inhibiting IL-2 
and IL-17A expression, while promoting IL-10 production (154-158). Additional studies 
have shown that IL-30 exhibits an anti-inflammatory role similar to IL-27. IL-27 can 
suppress IL-17A production, albeit at a much lower level than IL-27 (159). 
Recent studies have identified IL-30 as a critical regulator of breast and prostate cancer 
metastasis (160, 161). IL-30 is expressed in triple-negative HER2+ breast cancer tumors. 
In addition, expression of IL-30 was correlated with disease stage and re-occurrence. 
Mice injected with triple-negative HER2+ breast cancer cells treated with IL-30 displayed 
increased proliferation and vascular dissemination of breast cancer cells. Silencing of 
STAT1/3 signaling, downstream targets of IL-30, prevented the expression of CXCL1, 
CSF1, IL-1β, IL-6, IL-8, PTGS2/COX2, and Myc, which are known to promote tumor 
growth and metastasis (160). Expression of IL-30 has also been identified in prostate 
cancer cells and cancer infiltrating leukocytes (140). IL-30 expression is correlated with 
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grade and stage of disease in prostate cancer patients (162). Sorrentino and colleagues 
found that IL-30 secreted by human and murine prostate cancer stem-like cells (PCSLC) 
had significant autocrine and paracrine affects which supported PCSLC viability, self-
renewal, and tumorgenicity (161). Therefore, they concluded that IL-30 could be a 
potential target for development of therapeutic monoclonal antibodies for cancer 
treatment.    
Interleukin 31 
IL-31 was reported in 2004 by Dillon et al (163). It is a member of the IL-6 family of 
cytokines, a four-helix bundle cytokine which is produced by Th2 cells upon activation. It 
signals through a receptor composed of two chains, an IL-31 receptor A and oncostatin 
M receptor (OSMRbeta). The receptor is expressed constitutively in epithelial cells but is 
induced upon activation in monocytes. IL-31 seems to mediate pruritus, as this is an 
evident phenotype in IL-31 transgenic mice, which also develop alopecia and skin lesions. 
These observations strongly suggest that IL-31 is involved in dermatitis present in allergic 
diseases.  
Sonkoly et al. (164) showed that IL-31 is overexpressed in pruritic atopic dermatitis skin. 
Highest levels were observed in prurigo nodularis, one of the most pruritic forms of chronic 
skin inflammation. In vivo, staphylococcal enterotoxin B (SEB) (a super-antigen targeting 
Vβ8) induced IL-31 expression in atopic individuals, and in vitro SEB induced IL-31 
production in leukocytes. IL-31 receptor A showed the most abundant expression in 
dorsal root ganglia, the site where the cell bodies of cutaneous sensory neurons reside. 
Cells expressing IL-31RA mRNA were detected in the dorsal root and trigeminal ganglia, 
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and these cells also expressed OSMRbeta, but the expression of these receptor chains 
appear at different times during development (165). 
Expression of IL-31 correlates with the enhanced expression of IL-4 and IL-13 (two other 
Th2 cytokines) in atopic dermatitis and atopic contact dermatitis (166). However, IL-31 
mRNA was not observed increased in psoriasis. These observations strongly suggested 
that IL-31 is associated with itching, nevertheless, the situation may be more complex 
since other studies have found IL-31 levels strongly increased in Atopic Dermatitis but 
they do not correlate with the intensity of the disease according to the SCORAD severity 
score (167).  However, support for the concept that IL-31 is a pivotal cytokine regulating 
pruritus comes from studies on contact dermatitis with Il-31-/- mice which exhibit reduced 
scratching frequency and duration during hapten-induced contact dermatitis (168). 
Eosinophils can also be potent sources of IL-31 (169), and anti-IL-31 antibodies 
ameliorate scratching behavior in a mouse model of atopic dermatitis (170).  
Interleukin 32 
Kim et al. (171) reported the identification of a novel cytokine produced by a cell line 
(human lung carcinoma A549) transfected with an IL-18 receptor β chain. This rendered 
the cell responsive to IL-18 and it produced several cytokines, including a novel one they 
called IL-32. It is expressed by human peripheral blood mononuclear cells (PBMCs) upon 
activation, induced in human epithelial cells by IFNγ, and in NK cells by IL-12 plus IL-18.  
In fact, it was originally called NK Transcript 4. Its expression pattern mirrors other 
inflammatory cytokines so it is not surprising that it also is capable of inducing the 
production of other cytokines like TNFα, IL-1β, IL-6 and various CXC chemokines in 
various cells. There are various isoforms of IL-32, but the gamma isoform has been 
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reported to be the most active (172). IL-32 signals through p38 MAPK and NF-κВ 
pathways, and has been implicated in inflammatory disorders, inflammatory bowel 
disease, and influenza virus A infections. It has also been associated with several 
autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn’s disease 
(173). However, the specific role of this pro-inflammatory cytokine in these diseases is 
not yet known. It has also been implicated in the latent stage of tuberculosis (174). 
IL-32 is likely to have both intracellular and extracellular functions (175). It could be 
involved in resistance against intracellular pathogens (176). Intracellular IL-32 may be 
involved in regulation of cell activation and cell death. IL-32 also exhibits angiogenic 
properties (177).  
IL-32 has also been implicated in cancer progression. For example, IL-32 promotes the 
production of IL-2 by bone marrow cells which in turn may promote the proliferation of 
multiple myeloma cells (178). IL-32 expression has been associated with hypoxia in 
multiple myeloma cells, and high expression is associated with poor survival and bone 
loss (179). 
Given that there are various isoforms of IL-32, it represents a situation where each isoform 
may have different expression patterns, properties and functions. We can expect future 
more reports where specific isoforms of IL-32 will be functionally characterized.  
Interleukin 33 
IL-33 is a member of the Interleukin 1 (IL-1) superfamily. IL-33 induces Th2 responses in 
T cells, mast cells, basophils and eosinophils. Previously known as nuclear factor in high 
endothelial venules (NF-HEV) it was discovered in high endothelial cells.  Baekkevold et 
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al (180) discovered IL-33 by using molecular and bioinformatic approaches to study 
genes preferentially expressed by HEV endothelial cells, although it was found to be also 
expressed in human lymphoid organs (tonsils, lymph nodes and Peyer’s patches) and in 
single cells of the T cell zones of lymph nodes. Nevertheless, its function was uncertain, 
and it was pointed out as a possible transcription factor in charge of the regulation of 
expression after cytokine signaling in HEV cells.  
In 2005 researchers at Merck Research Labs showed that IL-33 signals through a ST2 
receptor, a previously orphan IL-1 receptor family member, which is expressed in human 
and murine Th2 cells, mast cells, eosinophils and basophils and it is involved in Th2 
responses  (181, 182). Using a pull-down method with biotinylated IL-33 to capture the 
ST2 receptor and a GFP-NF-κВ reporter transfected cell line Shmidtz et al proved that IL-
33 was binding and signaling through ST2 (Shmidtz and others 2005). Naturally, 
stimulation with IL-33 drives the expression of Th2 cytokines, IL-4, IL-5, and IL-13 and 
leads to an increase in the secretion of IgE, IgA and eosinophilia in vivo (182);(183). The 
connection of IL-33 with asthma and other Th2 related diseases was immediately drawn. 
Using microarrays, the group that originally reported IL-33, described that it is 
constitutively expressed in lymphoid tissues, epithelial cells, fibroblasts, mucosal tissues, 
tumor cells and vascular tissues where its expression is particularly high (184). The same 
group previously demonstrated that IL-33 has transcriptional regulation properties and 
that it can be located in the nucleus of high endothelial venules cells (HEVs), drawing a 
parallel to IL-1α  (182). IL-1α, another member of the IL-1 family that shares structural 
and functional characteristics with IL-33, such as the long 100 amino acid residues at the 
N-terminus and the presence in high concentrations as a precursor in the intracellular 
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compartment of expressing cells, rather than mature secreted forms due to the lack of 
signal peptide (185). The maturation and activity of IL-1 family members IL-1α, and IL-1β 
starts after the release from intracellular compartments mediated by mechanical or 
infection-related cell death, effectively making them representatives of molecules known 
as alarmins (186). Alarmins are the endogenous equivalent of pathogen-associated 
molecular patterns (PAMPs) and are released during non-programmed cell death. Once 
released alarmins can signal immune system cells such as macrophages and dendritic 
cells to initiate a cellular immune response to resolve inflammation (186). Given that IL-
33 is constitutively expressed in healthy barrier tissues, its similarities with other members 
of the IL-1 family of alarmins led the Girard group to conclude that IL-33 is an alarmin. 
Asthma leads to chronic inflammation and persistent airway remodeling in the lungs 
(187). IL-33 is upregulated in bronchoalveolar lavage fluid from asthma patients and a 
SNP polymorphism in ST2 is strongly associated with asthma in different human 
populations (188) (189). Yagami and collaborators showed that IL-33 acts directly in lung 
endothelial and epithelial cells but not fibroblast or muscle cells by inducing the 
expression of CXCL8, having a direct effect in controlling neutrophil recruitment to the 
lungs and thus regulating inflammation in the lungs (183). Furthermore in vitro stimulation 
of human microvascular endothelial cells from lung blood vessels (HMVEC-LBI) with IL-
33 also led to an increase of IL-6 and CCL2 secretion (183). From analysis of these data, 
we can conclude that IL-33 plays a major role in lung inflammation and that the IL-33/SP2 
signaling axis is important in the pathogenesis of asthma and allergies. 
Recently IL-33 has also been implicated in the regulation of immune responses in the gut. 
It has been reported that IL-33 is upregulated in patients with inflammatory bowel disease 
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(IBD) (190-192). Colonic T regulatory cells (Tregs) and group 2 innate lymphoid cells 
(ILC2s) are known to respond to IL-33 in the gut, reviewed in (193). Furthermore, IL-33 
has been shown to be a key cytokine in the maturation, proliferation and function of 
colonic Tregs, with an antagonistic activity to IL-23, a key inflammatory molecule of the 
gut (193, 194). From the research done in the last 15 years we can conclude that IL-33 
has emerged as a key regulatory cytokine in barrier tissues, making it an important target 
for inhibition therapy in autoimmune diseases such as IBD, rheumatoid arthritis (195), 
asthma, and allergies. 
We should note that a recent study on the ancestral origins of the Interleukin-1 family 
concluded that IL-33 and IL-18 have poor sequence similarity and no chromosomal 
evidence of common ancestry with the IL-1β cluster and therefore should not be included 
in the IL-1 ligand ancestral family (196). This observation has important functional 
implications. IL-33 and IL-18 therefore represent genes derived from an ancestral gene 
that also was the ancestor of the IL-1β cluster. However, since this split occurred a long 
time (millions of years) ago, each of these genes (IL-1β cluster, IL-18 and IL-33) has had 
a long time to evolve independently ever since. For this reason, we can predict that each 
of these genes should exhibit very different functional properties. In contrast, other IL-1 
family members derived directly from the IL-1β cluster in more recent evolutionary times 
should exhibit similar functions to other members of the IL-1β family cluster. 
Interleukin 34 
IL-34 is a cytokine that also binds the macrophage colony stimulating factor-1 receptor 
(CSF-1R). Its discovery was a ‘tour de force’. Lin et al (197) performed a functional 
screening of the extracellular proteome. This was represented by a comprehensive set of 
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recombinant secreted proteins and the extracellular domains of transmembrane proteins. 
Each protein was tested in several functional assays. One of the secreted proteins, 
designated IL-34, stimulated monocyte viability.  They also reported that IL-34 binds CSF-
1. However, it quickly became apparent that IL-34 and M-CSF did not exhibit identical 
biological activities. They differ in their capacity to induce the production of chemokines 
like CCL2 and CCL24 in primary macrophages. Interestingly, IL-34 and M-CSF do not 
share sequence homology, but some antibodies against CSF-1R can block the binding 
of one ligand but not another. This suggests that these ligands bind different parts of CSF-
1R, suggesting that they can mediate different bioactivities and signal transduction 
pathways. 
Both M-CSF and IL-34 mediate osteoclastogenesis (198) in combination with RANKL. 
This suggests a potential therapeutic role in osteoporosis.   
IL-34 is produced by keratinocytes in the skin and neurons in the brain. IL-34-/- mice 
displayed a marked reduction of Langerhans cells and microglia, whereas monocytes, 
dermal and lymphoid tissue macrophages were unaffected. Langerhans cell survival is 
dependent on IL-34, whereas microglia and their yolk sac precursors develop 
independently of IL-34 but rely on it for their maintenance in the adult brain (199).  
There have been other intriguing studies that have implicated IL-34. For example, Bezie 
et al reported that IL-34 is specifically produced by T regulatory cells and mediates 
transplant tolerance (200).  In a rat cardiac allograft model, treatment of rats with IL-34 
promoted allograft tolerance that was mediated by induction of Tregs. Treatment of 
human macrophages with IL-34 greatly expanded CD8+ and CD4+ FoxP3+ Tregs, cells 
that exhibited greater suppressive potential than non-IL-34 expanded Tregs.  
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In addition, IL-34 is known to influence the phenotype of myeloid lineage cells that express 
CSF-1R. For example, it has been reported to inhibit acute rejection of rat liver 
transplantation by inducing the polarization of Kupffer cells to the M2 phenotype (201). 
Similarly, it has been reported to be expressed at the fetal-maternal interface and to 
induce immunoregulatory macrophages of a decidual phenotype (202). 
IL-34 levels in serum have been reported in various diseases including systemic lupus 
erythematosus (203), periodontal disease (204), patients experiencing acute rejection 
following liver transplantation (205), development of liver fibrosis in patients with Hepatitis 
B (206) and rheumatoid arthritis (207). The potential role of IL-34 in these diseases 
remains to be clarified. 
Finally, IL-34 may play a role in both cancer and fibrosis. High co-expression of IL-34 and 
M-CSF correlates with tumor progression and poor survival in lung cancer (208). It also 
has been implicated in colon cancer (209), and it may play a role in the functional 
polarization of tumor-associated macrophages (210). It has been reported to promote 
fibrocyte proliferation, suggesting that it is a pro-fibrotic factor (211). 
We conclude that IL-34 has strong potential to be a target for development of therapeutic 
antibodies.   
Interleukin 35 
Interleukin 35 (IL-35) was named a decade ago (i.e. 2007) independently by two labs, 
Niedbala (212) and Collision (213), but it was first described in 1997 (213, 214). IL-35 has 
gained much interest for its role in strongly inhibiting immune cell function, with prospects 
in development of therapeutics for autoimmune disease. As part of the IL-12 family, IL-35 
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consists of a heterodimeric glycoprotein formed with disulfide linked IL-12alpha chain 
(p35) and IL-27 b chain Ebi3 (215). Collision et al originally reported that IL-35 was 
produced by populations of thymus-derived natural regulatory T cells (nTregs) and was 
required for their maximal suppressive activity (213). Regulatory Bregs have also been 
reported to produce anti-inflammatory cytokines including IL-10 and IL-35 (216), (60). Like 
other IL-12 cytokine family members, IL-35R binds to activate STAT proteins (217). 
Binding of IL-35 to IL-35R activates STAT1 and STAT4 in T cells (216). However, in B 
cells IL-35 signaling mediates STAT1 and STAT3 (60).  
IL-35 has gained much interest for its suppressive role. Ebi3 is a downstream target of 
FoxP3, restricting its expression to the Treg lineage. IL-35 has been shown to prevent 
Th1 and Th17 proliferation by arresting T cells in the G1 phase of cell division (218). 
Although IL-35 is able to block T cell proliferation, it does not promote the conversion of 
Th1 cells to Tregs as IFNγ is a strong negative regulator of Ebi3 and P35 transcription 
(144). In Th2 cells, IL-35 blocks Th2 differentiation by repressing GATA3 and IL-4 
expression. Additionally, IL-35, like TGF-β and IL-10, can induce regulatory T cells 
(iTregs). Recent studies have focused on the role of IL-35 in autoimmunity. Numerous 
studies have demonstrated that IL-35 plays a protective role in mouse models of human 
autoimmune disease such as, EAE, experimental autoimmune uveitis (EAU), 
encephalitis, allergic airway model, diabetes, and colitis (213, 219-222).  
Recently, Bregs have also been identified as potent producers of IL-35 (223) Bregs are 
believed to mediate their immunosuppressive capabilities through the secretion of IL-10 
upon stimulation of toll-like receptor agonists CD40L and IL-21 (224). Recent reports have 
suggested that IL-35 in addition to IL-10, contributes to Breg suppressive function. Bregs 
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have been shown to be capable of producing IL-35 (219), (60). Addition of rIL-35 results 
in selective proliferation of CD19+CD5+B220lo which display enhanced secretion of IL-10 
and IL-35. Similarly, rIL-35 inhibits B220hi B cell proliferation (219). IL-35 produced by 
Bregs acts in an autocrine manner to stimulate the IL-35R on Bregs and also in a 
paracrine fashion to promote the generation of induced Tregs (225).  
Alternatively, recent studies have suggested that IL-35 plays a protective role in tumor 
immune escape. Ebi3 overexpression has been reported in Hodgkin’s lymphoma (226), 
and lung cancer cells (227). In addition, tumors expressing IL-35 have an increase in 
myeloid derived suppressors cells (MDSCs), which are known to be immune suppressive 
and inhibit cytotoxic T cell responses (228).  
While IL-35 may be an intriguing cytokine to treat autoimmune diseases, recombinant IL-
35 is difficult to obtain, thus limiting immunology research and its potential production as 
a therapeutic. IL35 is not secreted as a disulfide-linked heterodimer, therefore only about 
4% of secreted Ebi3 is co-precipitated with IL-12p35 (214). Although approaches to 
generate rIL-35 in mouse models and attempts to covalently link Ebi3 and IL-12p35 have 
been made (60, 213, 229).   
While the immune inhibitory role of IL-35 has been well characterized in mouse models, 
the immunosuppressive effects of IL-35 in humans is modest (230). However, Seyeri et 
al reported that human Tregs produced IL-35 under strong stimulation (231). Thus, the 
role of IL-35 in human Tregs still warrants future investigation.  
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Interleukin 36 
IL-36 is a very interesting group of cytokines, derived from a member of the IL-1 family. 
In humans, they exist as 4 distinct secreted proteins, previously orphan IL-1 family 
ligands; IL-36α, IL-36β, IL-36γ and the receptor antagonist IL-36ra. All of them require 
post-transcriptional processing to be functional and bind the IL-36 receptor (IL-36R) (232). 
Due to the pro-inflammatory nature of all the IL-36 members and the similarity of the 
responses they elicit signaling through the IL-36R they were designated under the IL-36 
name in 2010 (233). 
The first member of the IL-36 cytokine group termed IL1HY1 (now IL-36ra) was 
discovered in 1999 by Mulero and collaborators, using a cDNA screening derived from 
human liver and spleen. The cDNA caught the authors’ attention due to the relatively high 
homology (65%) to IL-1ra (234).  The next year four different groups would publish the 
discovery of new members of the IL-1 family, (235-238). The function of these cytokines 
would not become apparent until their receptor was identified, IL-36R, formerly known as 
IL-1 receptor-related protein 2 (IL-1rp2). Debets and collaborators reported that IL-36α 
elicited NF-κВ signaling through IL-1Rrp2 and was strongly inhibited by IL-36ra (239). 
Interestingly, they also found high expression of IL-36α, IL-36ra and IL-36R in skin and a 
significant upregulation in lesional psoriasis. It was later found that all the proposed 
members of the IL-36 cytokine subfamily signal through IL36R and activate the NF-κВ, 
MAPKs, JNK and ERK1/2 kinase cascade which leads to CXCL8, TNF-α, IL-17A, IL-23 
and IL-6 secretion. Interestingly, IL-36ra functions as a direct antagonist of the other IL-
36 members (232, 240, 241). 
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IL-36R is mainly expressed in T cells and is especially predominant in naïve CD4 T cells 
(242, 243). Stimulation with IL-36 induced naïve T cell proliferation and enhanced IL-2 
secretion. Furthermore, IL-36β along with IL-12 promote Th1 polarization and plays an 
important role against Mycobacterium infections (242). IL-36 cytokines are mainly 
expressed in skin keratinocytes, myeloid cells, Langerhans cells and mucosal epithelium 
(243-245). This expression pattern and the responding cells indicate that the IL-36 
cytokines are likely very important in skin homeostasis and defense. As such, studies with 
an IL-36α-/- mouse showed that IL-36A (but not IL-36β or IL36γ) is required to induce and 
maintain psoriasis-like disease in a mouse model of psoriasis (246). Interestingly, the 
same group found that IL-36α acts in a self-amplifying loop with IL-1α, which is also 
required in order to maintain skin inflammation during psoriatic lesion flares (246).  
Ongoing clinical studies are currently evaluating the potential efficacy of IL-36R blockage 
using a therapeutic monoclonal antibody in psoriasis. A hint of the potential use of an IL-
36R blocking monoclonal antibody came from an unlikely source, a rare human disease 
caused by a loss of function mutation on the IL36RA gene, termed Deficiency of 
Interleukin 36 receptor antagonist (DITRA) syndrome (247). Patients with DITRA 
syndrome develop generalized pustular psoriasis (GPP) and some have been 
successfully treated with anakinra, a recombinant human IL-1RA originally developed for 
the treatment of RA (248-250). There is no certainty that the administration of IL-36R 
blocking antibody will help resolve skin inflammation in autoimmunity, but the concept is 
supported by a wide body of research that suggests that it will be effective in these 
indications. In fact, there are currently at least three active clinical trials testing the efficacy 
of a humanized anti-IL-36R antibody (251).  
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In recent years it has been observed that IL-36 family members, especially IL-36α, are 
upregulated during IBD pathogenesis (252). Walsh and collaborators found that the 
expression of IL-36α is upregulated in human patients with ulcerative colitis and mouse 
models of sterile inflammation. The inflammation was significantly reduced in a dextran 
sulphate (DSS) colitis model using IL-36r-/- mice. Furthermore, other studies indicate that 
IL-36 cytokines are also necessary for effective tissue repair in the gut (253, 254). These 
studies on the role of IL-36 family on IBD further improve the case for the development of 
IL-36R blocking therapies and highlights the need of further research on the role of IL-36 
cytokines in the homeostasis of the gut.  
Interleukin 37 
Another member of the IL-1 cytokine family, originally known as IL-1F7, shares structural 
similarities with IL-18 and can bind to the IL-18 receptor (IL-18Rα) although at much lower 
affinity (255, 256). It has 5 isoforms (IL-37a, b, c, d and e) and each isoform expression 
is tissue specific (257, 258). IL-37 was first described as an IL-1 family member (which 
was identified using the same approach that led to the identification of other IL-1 family 
members) through bioinformatics analyses of the human genome for uncharacterized 
genes that share similarity and/or share chromosomal location with other known IL-1 
family members. In fact, IL-37 was described along with the previously discussed IL-36 
cytokines simultaneously by three different groups using similar approaches (235, 237, 
255). Dunn and collaborators reported that IL-37 could bind to IL-18R suggesting a 
function similar or parallel to IL-18 (255). IL-36 is expressed in various tissues, but its 
expression is particularly high in thymus, testis and uterus as well as macrophages, DCs, 
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tonsillar B cells and plasma cells (259, 260). IL-37 is also expressed in gut and skin 
epithelial cancers (260). 
Remarkably, IL-37 is an anti-inflammatory cytokine. It was until 2010, almost 10 years 
after the first report by Nold and collaborators who found that the expression of IL-37 by 
epithelium and macrophages suppressed almost completely the expression of several 
pro-inflammatory cytokines (mainly IL-1β, IL-6 and TNF-α) and chemokines (CCL2, 
CXCL2 and CXCL8) in vitro and protected mice against sepsis induced by LPS in vivo 
(256). They also found that IL-37 forms a complex with SMAD3, an important transcription 
factor in the TGF-β pathway (261) and is necessary for IL-37 driven responses. Taken 
together, these observations indicated that IL-37 was likely to be a novel anti-
inflammatory cytokine. 
Most of the effects of IL-37 in metabolic, autoimmune and infectious diseases have been 
tested in several metabolic, autoimmune and infectious models using a transgenic mouse 
that overexpresses human IL-37 (IL37-tg) (256). In these experiments, IL-37 has proven 
to have a protective effect on tissue damage and mediates a reduction in the secretion of 
pro-inflammatory cytokines in several models including colitis, Rheumatoid Arthritis, 
allergy and fungal pulmonary infections (260, 262-265). Additionally, IL-37 appears to 
play a role in the regulation of fat metabolism, aortic disease and aging (266-268). 
Examination of the research done with IL-37 in mouse models of metabolic, autoimmune 
and infectious diseases indicates that IL-37 is important in homeostasis and as an 
immune regulator. While involvement of IL-37 has also been reported in human disease 
(269-272), there are currently no human clinical trials evaluating the effects of exogenous 
administration on humans. IL-37 seems as a potential candidate for supplementation 
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therapy in conjunction with blocking therapy (the most likely candidates would be 
monoclonal antibodies). 
Interleukin 38 
IL-38 is another IL-1 family protein discovered in the early 2000s along with IL-36 and IL-
37. The IL-38 gene was identified and termed IL-1HY2 by Lin and collaborators in 2001. 
They reported that IL-1HY2 shares sequence 52% and structural similarity to IL-1ra, and 
also significant similarity to IL-36ra (273, 274). The IL-38 gene is located in chromosome 
2, along with other members of the IL-1 family (275) indicating that it is part of recent 
evolutionary gene duplication. IL-38 is expressed in skin, fetal liver, placenta, brain, 
thymus and tonsils (273-275). Remarkably, years later van de Veerdonk and 
collaborators reported that IL-38 is an accessory IL-36 receptor antagonist that binds to 
the IL-36 receptor to decrease secretion of IL-22 and IL-17 after stimulation with heat-
killed Candida albicans in memory T cells. It also reduced the production of CXCL8 by 
PBMC induced by LPS, similar to the canonical IL-36ra (276).  The confirmation of IL-38 
binding to IL-36R came by using immobilized extracellular domains of the IL-1 family 
receptors to screen receptor binding and IL-38 and IL-36ra bound to the extracellular 
domain of IL-36 (276). Additionally, PBMCs treated with IL-38 siRNA produced up to 28-
fold more pro-inflammatory cytokines (including IL-36, CCL2 and APRIL), suggesting that 
IL-38 exhibits an antagonist function (277). 
Several genome-wide association studies (GWAS) studies have associated IL-38 with 
human diseases where other IL-1 family cluster alleles have been implicated including 
ankylosing spondylitis, RA and cardiovascular disease (278-281). IL-38 has been 
reported to be increased in patients with SLE and its levels directly correlate with an 
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increased risk of renal lupus and central nervous system lupus (277). It has also been 
found that IL-38 is increased in patients with hidradenitis suppurativa, hepatitis B, 
gestational diabetes mellitus, asthma, lung fibrosis and lung adenocarcinoma (282-287).  
Interestingly, in Hepatitis B, IL-38 expression appears to be a marker of good prognosis 
(patients with high levels of IL-38 were more likely to respond to therapy). In the case of 
asthma and cancer it appears to be the opposite, in asthma it correlated with lower 
numbers of circulating Tregs and in cancer it was associated with higher expression of 
PD-L1 by the tumors (284, 286, 287). The function and role of IL-38 has not been 
extensively explored and is one of the IL-1 family members for which less information is 
available. However, the data available strongly suggests that it is an attractive candidate 
to be a potential target for human diseases where the IL-36/IL-36R axis has been 
implicated.  
Interleukin 39 
In 2016, Wang et al described the most recently discovered member of the IL-12 cytokine 
family, Interleukin 39 (IL-39) (288). IL-39 is a heterodimer composed of the IL-23p19 
alpha subunit and Ebi3 beta subunit. IL-39 was found to be secreted as a heterodimer by 
activated B cells, similar to IL-35. Following LPS stimulation, IL-39 was significantly 
upregulated in B cells. In addition, p19 and Ebi3 mRNA was found to be expressed by 
DCs and macrophages (288). Similarly to IL-35, IL-39 has been shown to mediate 
inflammatory responses though activation of STAT1/STAT3 (289).  
SLE is an autoimmune disease in which B cells increase the production of autoantibodies 
(290). Wang and colleagues found that activated B cells in lupus-prone mice secreted IL-
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39. In addition, administration of IL-39 in vitro and in vivo induced the differentiation and/or 
expansion of neutrophils which contribute to disease (288, 291). Knock down of p19 or 
Ebi3 reduced lupus severity in mice. Therefore, targeting IL-39 may be used as a potential 
target for treating SLE. 
Future perspectives on cytokine discovery 
We have summarized the characteristics of the last 10 cytokines in Table III (an in-depth 
review of the latest one IL-40 will be done in the next chapters). It is apparent from 
the information already available on these proteins that their potential functional role(s) in 
both innate and adaptive immune responses and their potential role in human disease 
are vast. Still, it is obvious that the research focusing on these novel cytokines is still in 
early stages. As an example, a literature search on publications mentioning IL-10 in the 
US National Library of Medicine of the National Institutes of Health (pubmed.gov) yields 
56,241 publications, while a similar search for IL-35, one of the most “popular” new 
cytokines, yields only 409 results. This suggests that there are many novel fields of 
research to be defined based on the physiology of these novel cytokines.
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Table III. Summarized characteristics of new cytokines.  
Cytokine 
Other 
names 
Gene 
Superfamily 
Chromosome 
location 
Receptor Functions 
Main human 
expression 
tissues1 
Producing cells 
Immune cells 
responding 
Potential role in disease 
In-depth 
Reviews 
IL-30 
p28,  
IL-27p282 
IL-12 16p12.1 IL-27Rα 
Suppression of IL-17A 
production, Anti-Inflammatory  
Placenta, Bone 
Marrow, Liver, 
Stomach, Skin, 
Testis 
Monocytes,  
Macrophages,  
DCs 
T cells  Prostate Cancer, Breast Cancer (42) 
IL-31 None IL-6 12q24.31 IL-31RA/OSMRβ Pruritus, Pro-Inflammatory 
Bone Marrow, 
Tonsil, Spleen, Skin 
Eosinophils 
CD4+ T cells  
Epithelial cells, 
Monocytes 
Pruritic Atopic Dermatitis, Airway hypersensitivity, 
Inflammatory Bowel Disease 
(292) 
IL-32 NK4 None 16p13.3 Unknown 
Angiogenesis, IL-2 
production in bone marrow, 
Pro-Inflammatory 
Appendix, Lung, 
Duodenum, Small 
Intestine 
Monocytes,  
T cells,  
NK cells,  
epithelial cells 
Monocytes, 
Macrophages, Bone 
Marrow stroma 
Cancer, Tuberculosis, Influenza virus A infection, 
Rheumatoid Arthritis, Ulcerative Colitis, Chron's disease, 
Chronic Obstructive Pulmonary Disease 
(293); (294) 
IL-33 
NF-HEV,  
IL-1F11 
IL-1 9p24.1 ST2 Alarmin, Pro-Inflammatory 
Skin, Stomach, 
Cervix, 
Endometrium, 
Nasopharynx, 
Bronchus 
Endothelial cells, 
Epithelial cells, 
Fibroblast, 
Mucosal epithelium 
T cells, Mast cells, 
Eosinophils, Basophils, 
ILC2s 
Asthma, Inflammatory Bowel Disease (295) 
IL-34 C16orf77 None 16q22.1 
CSF-1R, PTP-ζ, 
CD138 
Myeloid cell proliferation, 
Anti-Inflammatory  
Spleen3, Skin3 
Keratinocytes, 
Neurons, 
Tregs, 
Monocytes, 
Macrophages,  
DCs 
Macrophages, 
Monocytes, 
Langerhans cells, 
Microglia, Kupffer cells, 
DCs 
Osteoporosis, Lupus, Periodontal disease, Hepatitis B, 
Rheumatoid Arthritis, Transplant rejection, Lung Cancer, 
Fibrosis 
(296) 
IL-35 None  IL-12 
3q25.33 
(IL12A); 
19p13.3 (EBI3) 
IL-12Rβ2/IL-
12Rβ2; 
gp130/gp130;  
IL-12Rβ2/gp130 
Prevents Th1 and Th17 cell 
proliferation, Induce 
Treg/Breg polarization, Anti-
Inflammatory  
Placenta, Spleen3, 
Tregs, 
Bregs,  
Macrophages, T cells  
Multiple Sclerosis, Diabetes, Colitis, Hodgkin lymphoma, 
Lung cancer  
(297) 
IL-36α  
IL-36β  
IL-36γ 
IL-36RA 
FIL1ε/IL1F6, 
FIL1η/IL1F8, 
IL1F9, 
FIL1δ/IL1F5 
IL-1 2q14.1 IL-36R  
Th1 responses, Pro-
Inflammatory 
Skin, Esophagus, 
Tonsil 
Keratinocytes, 
Mucosal epithelium, 
Monocytes, 
Macrophages, 
Langerhans cells, 
CD4+ T cells,  
Epithelial cells, 
Macrophages, DCs, T 
cells, B cells, Plasma 
cells  
DITRA4, Lesional Psoriasis, Tuberculosis, Inflammatory 
Bowel Disease  
(245) 
IL-37 FIL1ζ, IL-1F7 IL-1 2q14.1 IL-18Rα Anti-Inflammatory  Skin 
Epithelial cells, 
Keratinocytes, 
Monocytes, 
NK cells, 
B cells  
Epithelial cells, 
Fibroblasts, 
Monocytes, 
Macrophages, DCs, T 
cells 
Systemic Lupus Erythematosus, Rheumatoid Arthritis, 
Inflammatory Bowel Disease, Ankylosing spondylitis, 
Graves’ disease, HIV infection, Coronary Artery Disease 
(258) 
IL-38 
IL-1F10, 
FIL1θ 
IL-1 2q14.1 
IL-1R; IL-36R;  
IL-1RAPL1  
Blocking of IL-36, Anti-
Inflammatory  
Skin 
Epithelial cells, 
B cells 
Epithelial cells, 
Macrophages, DCs, B 
cells, Plasma cells  
Rheumatoid Arthritis, Atherosclerosis, Cardiovascular 
disease, Systemic Lupus Erythematosus, Hidradenitis 
suppurativa, Hepatitis B, Diabetes, Asthma, Fibrosis, 
Lung cancer 
(274), (298) 
IL-39 None IL-12 
12q13.3 (P19); 
19p13.3 (EBI3) 
Unknown Pro-Inflammatory  Spleen 
Macrophages, 
DCs, 
B cells 
Neutrophils Lupus None 
IL-40 C17orf99 None 17q25.3 Unknown 
Involved in IgA production, B 
cell homeostasis and 
development  
Bone Marrow, Fetal 
Liver 
B cells, 
Bone marrow stroma 
B cells  B cell lymphoma  None 
1 Data from protein atlas of human expression (https://www.proteinatlas.org) (299) 
2 IL-30 is a subunit of IL-27 but exhibits activity by itself 
3 RNA expression 
4 Deficiency of Interleukin 36 receptor antagonist is a disease caused by the lack of functional IL-36ra 
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One of the biggest challenges following the identification of a novel cytokine is to start 
defining its biology. Usually one of the first steps is the production of a knockout mouse. 
However, identifying a phenotype of a new knockout mouse is not easy either. These 
considerations make this type of research (searching for novel cytokines) a very 
challenging project. Importantly, evolutionary considerations can suggest functional roles. 
Even chromosomal location can provide important clues about the function of a particular 
gene (20). 
The discovery of cytokines in the late XX and early XXI centuries was supported by 
advances in molecular biology techniques and the development of gene databases and 
bioinformatics. Many of the cytokines, including several in this section, were found 
because they belong to cytokine super-families and share similarities to previously known 
cytokines. In our experience, the process that led us to the identification of IL-40, which 
is encoded by a previously uncharacterized gene for which no information was available, 
all the way to the identification of its role in IgA production and B cell development, has 
been difficult. A key question is whether there remain many other cytokines to be 
identified. Ten percent of the human genome is estimated to encode secreted proteins, 
suggesting that there may be more. Given the popularity of databases and gene arrays, 
and novel techniques like RNAseq and single cell sequencing, we may predict that 
cytokines produced by relatively rare cell subsets may yet be identified. If so, we would 
predict that their genes will not related to any of the known cytokine families. 
In the next chapter we will talk about the discovery of IL-40, a novel B cell cytokine. The 
discovery of a cytokine can be exciting and daunting at the same time. After identifying 
IL-40 in silico we had a few clues and tools to explore what IL-40 could be doing in the 
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immune system. As you will be able to see the roles of IL-40 in the immune system started 
to unfold as the analysis of the IL-40 knockout mouse (Il40-/-) proceeded. In this thesis we 
only describe the beginning of the research of IL-40 and, due to our results, we anticipate 
that in years to come more exciting new research about IL-40 will be published.  
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2.1 INTRODUCTION 
Cytokines are small secreted proteins that play an essential role in host defense, 
inflammation, the development of the immune system and in immune responses. 
Cytokines exert their effects by binding specific receptors on the membrane of target cells. 
The elucidation of cytokine receptor/ligand pairs has furthered our understanding of the 
mechanisms through which cytokines regulate the development of immune responses 
(1). Cytokine genes likely arose through gene duplication from ancient precursors (2), 
and therefore exhibit common structural features in their sequences that reflect their 
common evolutionary origins. This characteristic has facilitated the identification of all the 
members that belong to a particular cytokine superfamily (3). It follows that, if any 
cytokines remain to be discovered, they are not likely to be members of any known 
cytokine family.  
We sought to identify novel immune system-associated genes encoding either secreted 
or transmembrane proteins. To this end, we analyzed a comprehensive database of 
human gene expression (BIGE) that includes 105 different human tissues or cells (4, 5). 
These analyses led to the identification of 35 poorly characterized genes predicted to 
encode either transmembrane or secreted proteins expressed by either leukocytes or 
immune system-associated organs. We have reported three of these novel genes 
including Isthmin 1, TSPAN33 and Meteorin-like (6-8). Here, we report an 
uncharacterized gene (C17orf99: Chromosome 17 open reading frame 99), that encodes 
a small secreted protein (~27kDa) that is produced by B cells upon activation.  These 
characteristics strongly suggest that C17orf99 encodes a novel B cell-expressed 
cytokine. We therefore predicted that C17orf99 would have effects in the immune system. 
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To test this hypothesis, we obtained and analyzed a mouse with a targeted deletion of 
C17orf99. Phenotypic analysis of this mouse indicates that it exhibits altered B cell 
numbers, low levels of IgA in the serum, mammary gland and feces, and an altered 
microbiome. We conclude that C17orf99 encodes a novel B cell derived cytokine. 
Recently, a new member of the IL-12 family has been identified and named IL-39 (9, 10). 
We therefore have named the novel cytokine encoded by C17orf99 interleukin-40  (IL-40) 
(11); in this chapter, we demonstrate that IL-40 is a novel cytokine involved in the 
regulation of humoral immunity. 
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2.2 MATERIALS AND METHODS 
Cells. The human B cell line 2E2 (derived from a Burkitt’s lymphoma) has been described 
(12). The human T cell line Jurkat was obtained from the ATCC (American Type Culture 
Collection, Manassas, VA). The human B cell lymphoma cell lines have been described 
previously (16) and were a generous gift from Dr. David Fruman (University of California, 
Irvine, CA).The murine cell line A20-2J has been described (13) and was a kind gift of Dr. 
P. Marrack (National Jewish Health, Denver, CO). Human peripheral blood B cells were 
purified by flow cytometry (>95%). 
B40 cell differentiation. Mouse spleen B cells were isolated using Pan B cell isolation 
kit (Stemcell Technologies, Vancouver, Canada). B cells were plated (5x106 cells/well) in 
24 well plates and stimulated with anti-CD40 Ab (clone 3/23, Biolegend)  and anti-IgM 
(F(ab')2-Goat anti-Mouse IgM, Thermo-Fisher, MA)  (5µg/mL) alone, or in presence of IL-
4, TGF-β, (both at 10ng/mL, Biolegend) or IL-21 (30 ng/mL, Biolegend) for 2 days. Cells 
were lysed and processed using Trizol reagent (Invitrogen, CA). 
qRT-PCR. Human cDNAs were obtained from Clontech (Mountain View, CA) and PBMCs 
from Sanguine Biosciences (Sherman Oaks, CA). RNA was isolated from human cell 
lines/cells or tissues using the QiagenRNeasy® kit according to the manufacturer’s 
instructions (Qiagen, Valencia, CA). cDNA reaction performed using the QuantiTect® 
Reverse Transcription (Qiagen). qPCR was performed using the Roche LightCycler® 480 
Real-Time PCR system with probes designed to detect CD19 (B cell marker), C17orf99 
and GAPDH (housekeeping gene) (Roche, Pleasanton, CA) (Table IV).  The mouse gene 
homolog of human C17orf99 is 6030468B19. 
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Table IV. qRT-PCR oligonucleotides used in this study 
 
Mice. All animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC), of the University of California, Irvine. MRL/MpJ-Faslpr/J mice (Stock 
number 000485) were obtained from the Jackson Laboratory (Bar Harbor, ME). C57BL/6J 
(stock number 000664) were obtained from the Jackson Laboratory. Il40-/- mice 
(B6/129S5-6030468B19Rik-/-) were obtained from the Knockout mouse repository 
(KOMP), (UC Davis, Davis, CA). The B6/129S5-6030468B19Rik-/- mice obtained were 
backcrossed to C57BL/6J (stock number 000664) at least 5 generations. Wild Type (WT) 
mice used as controls were littermates from het/het pairings that also yielded 
homozygous Il40-/- mice. Serum samples were obtained through sub-mandibular cheek 
bleed as described (14). Fecal samples were collected as described (15). Breast milk 
samples were obtained by collecting the stomach contents of neonate mice. Briefly, 
stomach contents were centrifuged at max speed for 15 minutes and supernatants were 
collected. Genotyping was done by PCR usin primers IL40 Wt Fwd (5’-GGG GGC AAA 
ATT CAC CTG TT-3’), IL40 Wt Rev (5’-TAC CGG GAC TAC TGG GGA GAA-3’), IL40 
KO Fwd (5’-CAG TCT GCC CTT GTC CAC TC -3’) and IL40 KO Rev (5’-GCA GCG CAT 
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CGC CTT CTA TC-3’). Amplicons expected are 420 bp for Wt and 320 bp for Il40-/- mice, 
both for Heterozygotes. 
ELISA. ELISA assays were performed according to each manufacturer’s protocols 
(Ebioscience, San Diego CA). Plates were read at 450nm. For fecal IgA ELISA plates 
(Sigma Aldrich, St Louis, MO) were coated with anti-IgA mAb (clone RMA-1) (BioLegend, 
San Diego CA) at 2µg/ml. 5% milk in PBS-T was used as blocking buffer. Plates were 
washed 3 times with PBS-T after each step. AP conjugated anti-mouse IgA (Southern 
Bio, Birmingham, AL) used as secondary antibodies for 1 h at room temperature and 
washed 3 times with PBS-T. SureBlue substrate (KPL Gaithersburg, MD) was added, 
reaction was stopped with 2N H2SO4. Plates were read at 630nm. 
Western Blot.  In order to verify that IL-40 is secreted, human IL40 cDNA was cloned 
from human 2E2 B cells, a Burkitt’s lymphoma model of B cell activation and 
differentiation(12), and inserted into pTT5 vector(16) resulting in a recombinant gene 
encoding a fusion protein with a C-terminal 8x Histidine (HIS) tag. HEK 293 cells were 
transiently transfected with the pTT5-IL40 construct, (or empty vector as a control), and 
day 1 and day 3 supernatants were collected, concentrated in an anti-HIS column 
(GenScript), and analyzed for the presence of recombinant IL-40 protein by Western blot 
(using anti-His antibody)(Bio-Rad).  
Flow cytometry. Peyer’s patches were isolated from the small intestines of WT and IL40-
/- mice. Peyer’s patch B cells were stained with phycoerythrin (PE)-Labeled anti-mouse 
CD45R (B220), rat mAb (RA3-6B2, eBioscience) and FITC-labeled PNA (E-Y 
Laboratories, San Mateo, CA), 7AAD (BioLegend), and APC-labeled IgM (BioLegend) 
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and analyzed by flow cytometry using BD FACSCalibur (BD Biosciences San Jose CA) 
using Flowjo data analysis software (TreeStar Inc., Ashland OR). 
Bone marrow cells were isolated from femurs of C57BL/6J and IL40-/- mice. The cells 
were isolated by flushing cells out with a 25G needle with FACS buffer (PBS 5% HI 
FBS). The cells were stained with monoclonal conjugates, as follows; PE anti-mouse 
CD45 conjugate (30-F11; Biolegend, CA, USA), FITC anti-mouse CD11b (M1/70; 
Biolegend), BV421 anti-mouse B220 (RA3-6B2; Biolegend), anti-mouse CD51 (RMV-7, 
Biolegend) and Fixable Viability dye eFluor 760 (eBioscience) in FACS buffer for 20 
minutes and sorted using a FACSaria Fusion sorter (BD Bioscience). The data were 
analyzed with FlowJo V10.0.8 software (TreeStar Inc.). 
Bone Marrow B cell subsets. Mice of 8 weeks were used for FACS analyses of the bone 
marrow. Single bone marrow cell suspensions were stained using anti-mouse antibodies 
against B220 (RA3-6B2, eBioscience, CA, USA), CD19 (1D3, eBioscience), CD43 (S7, 
BD bioscience, NJ, USA), IgM (RMM-1, Biolegend, CA, USA), IgD (IA6-2, Biolegend), 
cKit (2B8, eBioscience), Flk2 (A2F10, eBioscience), Ter119 (Ter119, eBioscience) and 
B220 (6B2, eBioscience). The gating was done as described in (17, 18). 
Splenic B cell subsets analyses. Spleens from mice of 8 weeks of age were used for 
analysis. Single splenocyte suspension were stained with anti-mouse antibodies 
(Biolegend, CA, USA) anti CD19 (HIB19), anti-CD93 (AA4.1), anti IgD (IA6-2), anti IgM 
(RMM-1), anti CD21/35 (CR2/CR1) and anti CD23 (B3B4).  The gating strategy was done 
as described by Allman and Pillai (19). 
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Class Switch Recombination Assay. This assay was performed as described in (20, 
21). Briefly, B cells were purified from splenocyte suspensions using a MojoSort pan B 
cell isolation kit (Biolegend) following the manufacturer’s protocol.  B cells were cultured 
at 50x103/ml in RPMI supplemented with 10% and 50 μM BME, and stimulated with 
LPS (10 µg/ml) for CSR to IgG3.  Additionally, B cells were stimulated with LPS (10 
μg/ml) and with the following cytokines and reagents: IL-4 (5 ng/ml) for CSR to IgG1; 
TGF-β (5 ng/ml) for CSR to IgG2b; IL-4 (5 ng/ml), IL-5 (5 ng/ml), anti-IgD/dextran (10 
ng/ml) and TGF-β for CSR to IgA. Cells were harvested by centrifugation at 500XG, 
stained with antibodies to B220, IgM, IgG1, IgG2b, IgG3, IgA and CD138, and analyzed 
by flow cytometry as described above. 
Statistical analyses. We utilized the unpaired Students T test for all experiments. 
Differences with p < 0.05 were considered statistically significant and are labeled as 
follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Error bars represent Mean 
plus/minus SEM. 
Microbiome Analyses. DNA extracted from fecal samples was amplified by PCR of 16S 
rDNA (V4 region) with primers 515F and 806R modified by addition of barcodes for 
multiplexing, then sequenced on an Illumina MiSeq system (UC Davis HMSB Facility). 
Sequences were processed and analyzed by employing the QIIME (22) pipeline v1.9.1 
with default settings, except as noted. In brief: paired-end sequences were joined, quality 
filtered, and chimera filtered (usearch61 option, RDP gold database); operational 
taxonomic units (OTUs) were picked de novo (‘pick_otus’ options: 
enable_rev_strand_match True, otu_picking_method usearch61) at 97% similarity, 
employing the SILVA rRNA gene database v123 (23, 24) (align_seqs:template_fp 
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core_alignment_SILVA123.fasta; ‘filter_alignment’ options: allowed_gap_frac 0.80, 
entropy_threshold 0.10, suppress_lane_mask_filter True); taxonomy was assigned with 
the RDP classifier (‘assign_taxonomy’ options: assignment_method rdp, confidence 0.8, 
rdp_max_memory 24000, reference_seqs_fp 97_otus_16S.fasta, id_to_taxonomy_fp 
consensus_taxonomy_7_levels.txt). Samples were rarefied to 10,000 reads, then alpha 
(Shannon index) and beta (unweighted and weighted UniFrac) diversity were assessed 
via QIIME. Prism 7 software (Graphpad) was utilized for statistical analyses (Mann-
Whitney-U). 
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2.3 RESULTS 
C17orf99 encodes a novel cytokine 
Analysis of the BIGE database led to the identification of several poorly characterized 
genes encoding either transmembrane or secreted proteins and expressed by cells or 
organs of the immune system. Further bioinformatics analyses led to the identification of 
an uncharacterized gene annotated as C17orf99 (Chromosome 17 open reading frame 
99) that encodes a small secreted protein (~27KDa). Other than its identification as one 
of 472 genes reported in a large study aimed at the identification of poorly characterized 
or unknown human genes encoding either transmembrane or secreted proteins(25), and 
a previous gene survey predicting that C17orf99 encodes a small secreted protein(26), 
there is currently no information on C17orf99 in the literature. The BIGE database (which 
consists of microarray data) indicates that C17orf99 is expressed in fetal liver and bone 
marrow as well as activated B cells (Figure 2.1a). C17orf99 encodes a small secreted 
protein of 265 amino acids (including a 20 amino acid signal peptide) predicting a mature 
protein of ~27 kDa (Figure 2.1b). We confirmed these data in human tissues by end-point 
PCR (Figure 2.1c). Since C17orf99 is currently an unannotated gene of unknown 
function, we performed further bioinformatics analyses and BLAST searches, specifically 
looking for shared synteny among different genomes. These analyses revealed that 
C17orf99 is only present in mammalian genomes (Figure 2.1d). To confirm that it 
encodes a secreted protein, we transfected the predicted human C17orf99 open reading 
frame with a HIS tag into HEK293 cells. Supernatants were analyzed for the presence of 
recombinant C17orf99 protein using an anti-His antibody. A band between 23 and 30kDa 
(consistent with a ~27kDa protein) was detected in cell cultures transfected with the 
 72 
 
pTT5V5H8-C17orf99 construct, (Figure 2.1e), confirming that C17orf99 encodes a 
secreted protein. We also confirmed the expression of C17orf99 mouse and human 
tissues by qPCR (Figure 2.2). 
 
Figure 2.1. C17orf99 encodes a novel cytokine (interleukin 40). (a) C17orf99 expression 
in normal human tissues and immune cells from the BIGE (Body Index of Gene 
Expression) database. IL-40 is expressed in fetal liver, bone marrow, and peripheral blood 
B cells activated with anti-CD40 and IL4. (b) C17orf99 amino acid sequence showing the 
predicted signal peptide (underlined). (c) RT-PCR of C17orf99 showing a positive band 
in human fetal liver (FL) and bone marrow (BM) but not in Thymus (T) or lung (L) (which 
were used as controls), one experiment out of three independent experiments shown. (d) 
Clustal Omega analyses of the C17orf99amino acid sequence in 10 selected mammalian 
species. C17orf99 homologs exhibit a minimum sequence homology with human 
C17orf99 (at the amino acid level) of 55% and a maximum E value of 3 x e-70). (e) 
Western blot of supernatant from day 1 (D1) or day 3 (D3) of cultures of HEK293 cells 
transfected with IL-40pTT5V5H8-C17orf99-HIS vector. Supernatants were concentrated 
in an anti-His column before being run in western blots with anti-HIS antibody. 
Representative of two independent experiments; (M): molecular weight ladder. 
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Figure 2.2. IL-40 expression in mouse and human. IL-40 expression is conserved in 
human and mice (72% homology at the amino acid level). (a) Human and mouse 
primary protein structure alignment. (b) qPCR expression pattern of human tissues. (c) 
qPCR expression pattern of mouse tissues. 
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C17orf99 encodes a secreted protein produced by activated B cells.  
The expression of C17orf99 in bone marrow and fetal liver suggested a hematopoietic 
function.  We initially hypothesized that it would be expressed by stromal cells, since 
these cells express many hematopoietic cytokines (27). We analyzed various freshly 
harvested mouse bone marrow cell populations for expression of the mouse homolog of 
human C17orf99 (6030468B19Rik) and observed that its expression decreased rapidly 
following culture in vitro. By 48 h following culture the expression of C17orf99 was 
undetectable. We then FACS-sorted various bone marrow cell populations and performed 
q-PCR for C17orf99. As shown in Figure 2.3, the main source of C17orf99 expression in 
the bone marrow is Lin-CD45- cells (representing mostly stromal cells), while very low 
expression was detected in the CD45-CD45+ compartment (that comprises mostly 
precursor and immature lymphocytes), and no detectable expression was observed in 
Lin+CD45+ cells or any cell expressing CD45 (that represent myeloid, B cells, T cell 
precursors and DCs).  
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Figure 2.3. IL-40 is expressed by Lin-CD45- in the BM. BM cells were sorted using 
leukocyte marker CD45, precursor cell marker Kit and B cell precursor marker IL-7r (a) or 
CD45 and Lineage (Lin) markers (Gr-1, F4/80, CD11b, CD3 and CD19) (b). qRT-PCR 
was performed on the sorted cells measuring the expression levels of IL-40. 
Representative of 3 separate experiments. 
 
The BIGE database indicates that besides bone marrow and fetal liver, activated (with 
anti-CD40 and IL4) human peripheral blood B cells also express C17orf99 (Figure 2.1a). 
We therefore studied the expression of C17orf99 by B cells. As shown in Figure 2.4a, 
activation of the mouse B cell lymphoma A20-2J (13) with CD40L and IL-4 induced strong 
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expression of C17orf99. Spleen B cells from Wild Type (WT) C57BL/6 mice activated with 
anti-CD40 and IL-4 also express C17orf99 (Figure 2.4b). We next tested several 
activating stimuli on these cells, including various cytokines, and observed that B cells 
require several stimuli for optimal expression of C17orf99. These include a B cell receptor 
stimulus (anti-IgM), anti-CD40, and several cytokines. Interestingly, TGF-β strongly 
potentiates the expression of C17orf99 by activated B cells and the strongest expression 
was observed when B cells were activated with aCD40+anti-IgM+IL-4+TGF-β (Figure 
2.4b). Taken together, the characteristics of C17orf99 (encoding a small (~27 kDa) 
secreted protein, expressed upon activation by B cells) strongly suggests that C17orf99 
encodes a novel B cell-derived cytokine that we have called interleukin 40 (IL-40) (11), a 
nomenclature we will use in this study. 
Since we observed the upregulation of Il40 in response of TGF-β we wanted to know if 
IL-40 is produced by Breg cells. Bregs can secrete IL-10 and TGF-β in response to CD40, 
BCR crosslinking, IL-4 and IL-21 stimulation in vitro (28). We stimulated B cells from 
spleen in the presence or absence of IL-21 and measured the expression of IL-40 and IL-
10. Surprisingly we found that IL-21 downregulated the expression of IL-40 while TGF-β 
inhibited the expression of IL-10 (Figure 2.4c). Several cytokines and immunogens (such 
as LPS) were tested before with the only treatment able to upregulate the expression of 
IL-40 is shown in Figure 2.4b. Taking these results together we propose that IL-40 is 
secreted by a specialized effector B cell subset that we call B40 cells. 
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Figure 2.4. IL-40 production is induced upon B cell activation. (a) IL-40 production by 
mouse A20-2J cell line stimulated with anti-CD40 mAb and IL-4 for 24h, representative 
of 2 independent experiments (Mean +/-SEM) (** p < 0.01) (qRT-PCR). (b) qRT-PCR 
analysis of Il-40 expression in mouse spleen B cells stimulated with anti-CD40 Ab and 
anti-IgM (5µg/mL) alone, or in presence of IL-4, or TGF-β, (all at 10ng/mL) for 2 days, fold 
expression compared to resting cells, representative of three independent experiments 
(Mean+/-SEM)(*p<0.05, **p<0.01). (c) qRT-PCR analysis of Il-40 expression in mouse 
spleen B cells stimulated with anti-CD40 Ab and anti-IgM (5µg/mL) alone, or in presence 
of IL-4 (10ng/mL), TGF-β, (10ng/mL) or IL-21 (30 ng/mL) for 2 days. Representative of 
three independent experiments. 
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IL-40 expression is induced upon the onset of lactation in the mammary gland. 
IL-40 is 72% conserved at the amino acid level between mouse and human (Figure 2.2a) 
and exhibits a similar expression profile between the two species (Figures 2.2b; human 
and 2.2c; mouse). As shown in Figure 2.1d, C17orf99 is present only in mammalian 
genomes, and is expressed by activated B cells (Figure 2.5). We therefore hypothesized 
that it may be involved in mammalian-specific functions such as lactation. To test this 
hypothesis, we measured the expression of Il40 in virgin, pregnant, 1 week post-natal 
(PN), and 3 week PN mammary glands of WT C57BL/6 mice. As shown in Figure 2.5a, 
Il40 expression is induced upon the onset of lactation and correlates with the onset of IgA 
production in the mammary gland (Figure 2.5b). 
  
 79 
 
 
 
Figure 2.5. IL-40 expression is induced in the mammary gland upon the onset of lactation 
and the Il40-/- mouse exhibits decreased IgA levels in milk. (a) qRT-PCR analysis of Il-40 
expression in WT virgin, pregnant, 1-week post-natal (PN) lactating, and 3-week PN 
lactating mouse mammary glands (Mean+/-SEM) (*p<0.02, **p<0.001). (b) qRT-PCR 
analysis of IgA expression in WT virgin, pregnant, 1 week post-natal (PN), and 3-week 
PN (Mean+/-SEM) (*p<0.029). (c) Total number of T or B cells in spleens from WT or Il40-
/- mice (n=5 per group, (Mean+/- SEM) (*p<0.038) Shown is a representative experiment 
(out of three). 
 
An Il40-/- mouse exhibits B cell abnormalities  
To further explore the role of IL-40 in the immune response, we obtained a mouse with a 
targeted deletion of the mouse homolog of C17orf99 (6030468B19Rik), which has been 
described as part of a large mouse knockout database (25), and that results in complete 
absence of IL-40 expression. This Il40-/- mouse is viable and reproduces normally.  We 
hypothesized that this mouse would exhibit B cell abnormalities. The Il40-/- mouse has 
less B cells in the spleen compared to WT (Figures 2.6a) indicating that the absence of 
IL-40 affects B cell homeostasis.  To obtain more information about the effects of IL-40 in 
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splenic B cells we analyzed transitional and marginal zone B cells from Il40-/-mice, by flow 
cytometry and observed a significant reduction in the number of transitional, follicular and 
total marginal zone B cells (Figure 2.6b). These observations confirm that IL-40 is 
involved in peripheral B cell homeostasis. 
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Figure 2.6. B cell populations are altered in the Il40-/- mouse. (a) Total B cells (CD19+) in the WT or Il40-/- mice. (b) B cell 
subpopulation analysis in the spleen. Transitional B cells (T1: CD23−CD93+IgMhighIgD−/lowCD21/35−/low; T2: 
CD23+CD93+IgMhighIgDhighCD21/35low; T3: CD23+CD93+IgMlowIgDhighCD21/35low), Total Follicular B cells (Follicular: 
CD23+CD93−CD21/35int.), Follicular 1 (Fol 1: CD23+CD93−IgMlowIgDhighCD21/35int) and Follicular 2 (Fol 2: 
CD23+CD93−/lowsIgMhighsIgDhighCD21/35int), Total Marginal zone B cells (MZ total: CD93−/lowIgMhighCD21/35high), Marginal 
zone (MZ: CD23−CD93−IgMhighIgDlowCD21/35high) and Marginal Zone Precursors (MZP: 
CD23+CD93−/lowIgMhighIgDhighCD21/35high) all of the cells were CD19+. Bars represent +/- SEM, n=4 per group. 
Representative of two independent experiments. *p=<0.05, **p=<0.002. 
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B cell populations are altered in the BM of Il40-/- mice 
The Il40-/- mouse exhibits a deficiency of B220+ cells in the bone marrow. B220 is a B cell 
lineage marker that is expressed by B cell progenitors (pre-B cells) during development 
in the mouse bone marrow (29). B220+ cells account for approximately 20% of the cells 
in the bone marrow of normal adult mice (30). We stained for the stromal and progenitor 
cells (CD45-) and leukocytes (CD45+), which were in turn divided into the B cell 
compartment (CD45+B220+), myeloid compartment (CD45+CD11b+) and T cell 
progenitors (CD45+CD11b-)(31, 32). We observed a significant reduction in the number 
of B220+ cells in the bone marrow of Il40-/- mice (Figures 2.7a and 2.7b) which include 
precursor and mature B cells in the BM. These data suggest that IL-40 is involved in the 
development of B cells. Because BM expresses IL-40 (Figure 2.1a), we tried to further 
identify the cells that produce IL-40. We had observed that CD45- bone marrow cells 
express IL-40 (Figure 2.3). The CD45+ population contains B cells precursors (Pro-B, 
Pre-B cells), while the CD45- lineage negative (CD3, Ly-6G/Ly-6C, CD11b, B220 and Ter-
119) population represents mostly stromal cells. We sought to subdivide the CD45- 
population by the expression of Lin markers and CD51 (αV integrin) (33). As shown in 
Figure 2.7c, IL-40 is strongly expressed by CD45-Lin-CD51- population, which contains 
mostly mature stromal cells (33). We also analyzed the B cell precursor populations in 
the BM and found reduced numbers of pre-B cells (Figure 2.7d and Figure 2.8). Taken 
together, the fact that some BM stromal cells produce IL-40, whereas there are alterations 
in the B cell precursor compartment in the BM, strongly suggests that IL-40 plays a role 
in B cell development.
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Figure 2.7. IL-40 is highly expressed in BM stroma and is required for normal B cell homeostasis. (a) Bone marrow staining 
of different cell compartments: stromal cells (CD45-), leukocytes (CD45+), the B cell compartment (CD45+B220+), myeloid 
compartment (CD45+CD11b+) and T cell progenitors (CD45+CD11b-). Shown is a representative plot of n=5 per group and 
is representative of two independent experiments. (b) Total cell count for each compartment in c. Results shown are 
representative of two independent experiments. (c) qPCR of sorted stromal populations in the bone marrow. Whole bone 
marrow expression (BM), stromal precursors (CD45-CD51+) and mature stroma (CD45-CD51-). Relative expression 
compared to whole bone marrow (BM). Data are representative of two independent experiments. (d) Number of pre-B cells 
(CD19+, B220+, IgM-, IgD-, CD43-) in BM of WT and Il40-/- mice. *p < 0.05. 
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Figure 2.8. Total cells and B cells are reduced in the BM of Il40
-/-
mouse (a) Gating 
strategy for analyses of B cell populations in the bone marrow. (b) Total number of cells 
and B cell populations in the bone marrow of WT and Il40
-/-
 mice. B cells (CD19
+
,B220
+
), 
Pre-Pro B cells (B220
+
, IL7R
+
, Flk2
+
, Ly6D
+
), Pro-B (CD19
+
, B220
+
, IgM
-
, IgD
-
, CD43
+
), 
Immature B cells (CD19
+
, B220
+
, IgM
+
, IgD
-
), and mature recirculating B cells (CD19
+
, 
B220
+
, IgM
+
, IgD
+
). Bars represent mean +/- SEM, n=4 per group, *p < 0.05. 
Representative of two independent experiments.  
 
We have also analyzed hematopoietic stem cell populations in the bone marrow (short 
term hematopoietic stem cells, long term hematopoietic stem cells, common lymphoid 
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progenitors, common lymphoid progenitors, B lymphocyte progenitors’ common myeloid 
progenitors, granulocyte-macrophage progenitors and megakaryocyte and erythrocyte 
progenitors) and found no significant alteration in the Il40-/- mice bone marrow compared 
to WT mice (Data not shown). These data suggest that IL40 does not affect 
hematopoiesis. 
Il40-/- mice exhibit reduced levels of IgA in mucosal secretions and exhibit GALT 
abnormalities.  
Lactation triggers the onset of IgA production in the mammary gland. Several genes have 
been implicated in IgA production in the mammary gland. For example, a CCR10-/- mouse 
has no IgA in the milk, because the CCL28/CCR10 chemokine axis mediates the 
recruitment of IgA plasmablasts to the lactating mammary gland (34).  We therefore 
explored whether IgA production is affected by the absence of IL-40. To this end, we 
analyzed gut associated lymphoid tissue (GALT), which contains a large number of 
immune cells and is a preferred site of IgA responses (35), in Il40-/- or WT mice. Peyer’s 
Patches (PPs) are GALTs that participate in immune surveillance of the digestive tract, 
and contain both germinal center B cells and IgA-secreting plasma cells (35). The Il40-/- 
mouse has fewer and smaller PP than WT mice (Figures 2.9a) (36, 37). Since IgA is the 
main immunoglobulin produced at this site (36-38), we measured total IgA switched cells 
(IgA+) and found a 5-fold reduction in total IgA positive cells (Figures 2.9b, 2.9c and 
2.9d). Taken together, these data indicate that IL-40 participates in the development of 
IgA responses in the GALT, especially in the PP. Given these results, we next measured 
IgA levels in the serum, feces or milk of WT or Il40-/- mice and observed a significant 
reduction in IgA levels in the Il40-/- mouse (Figures 2.9d-g). The lower levels of IgA in 
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feces of the Il40-/- mouse correlate with defects observed in the Peyer’s Patches (Figures 
2.9a-d). Serum levels of IgM and total IgG were unaffected (data not shown). We then 
hypothesized that the defects in IgA production may be due to defects in class-switch 
recombination (20). To test this, we performed a class switch recombination assay but 
did not detect differences when using cells from Il40-/- or WT mice, suggesting that this 
mechanism is not affected by lack of IL40. (Figure 2.10). Based on these observations, 
we conclude that IL-40 is involved in the development/control of humoral immune 
responses, especially those involving IgA production. 
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Figure 2.9. Il40-/- mice exhibit defects in GALT B cell populations. (a) Total counts of 
Peyer’s patches (PP) from WT or Il40-/- mice (Mean+/- SEM) (n = 7) (*p<0.0102). (b) Flow 
cytometry analysis of germinal center B cells from PP showing lower numbers of IgA+ B 
cells. (c) Total number of IgA+ cells from (b) (x10-5) (****p<0.01). (d) Serum IgA levels in 
Il40-/- mice compared to WT controls as measured by sandwich ELISA (n=8) (Mean+/- 
SEM) (*p<0.0114). (e) Measurements of total IgA in fecal pellets by sandwich ELISA of 
WT vs Il40-/-mice (Mean+/-SEM) (n=10) (***p<0.006) are representative of 3 independent 
experiments, each performed with 5 mice per group. (f) Measurement of total IgA in breast 
milk by sandwich ELISA of WT vs Il40-/-mice, (Mean+/- SEM) (WT n = 5; Il40-/- n = 6) 
(****p<0.0001). 
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Figure 2.10. B cells from IL-40 wt and IL-40 -/- mice were measured by in vitro stimulation 
and flow cytometry assays for their relative ability to undergo CSR to the indicated 
isotypes and plasmablast/plasma cell differentiation.  B cells were stimulated for 4 days 
with LPS and the following cytokines inducing isotype-specific CSR: IL-4, IL-5, TGF-β and 
anti-IgD/dextran for IgA (a), IL-4 for CSR to IgG1 (b); TGF-β anti-IgD/dextran for CSR to 
IgG2b (c); LPS alone to induce IgG3 (d). B cells stimulated with LPS and IL-4 for 4 days 
were measured by flow cytometry for the percentage of IgG1+ CD138+ class-switched 
plasmablasts/plasma cells (E). Panels on the right of each set of plots indicate results 
from triplicate experiments. 
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An Il40-/- mouse exhibits microbiome abnormalities 
The gut is one of the major producers of IgA of the body (39, 40). IgA is an important 
regulator of commensal bacteria in the gut and controls infections in mucosal secretions 
(40). We hypothesized that the low levels of IgA measured in Il40-/- mice could be affecting 
the composition of the intestinal microbiome. To test this hypothesis, we collected fecal 
samples from WT and Il40-/- mice to perform total DNA extraction and 16S sequencing. 
Eubacterial diversity was reduced in the Il40-/- mouse, and both the community 
composition and structure were substantially different by the absence of IL-40 expression 
(Figures 2.11a-b). At the phylum level (Figure 2.11c), we observed a significant 
reduction of Firmicutes in Il40-/- mice relative to WT, with a concomitant increase in 
Bacteriodetes. Deeper analysis of the affected phyla revealed significantly altered families 
and genera in the Il40-/- mouse. Among the Bacteroidetes, the uncultured Bacteroidales 
family S24-7(41) was significantly increased (mean = WT 36.99%, Il40-/- 70.02%; **). For 
the Firmicutes, the family Lachnospiraceae was the most prominent among those 
significantly reduced (WT 45.54%, Il40-/- 11.93%; **), reflecting decreases in genera such 
as Blautia (WT 0.48%, Il40-/- 0.02%; **), Coprococcus 1 (WT 0.58%, Il40-/- 0.07%; **), 
Roseburia (WT 2.37%, Il40-/- 0.13%; **), and UCG-001 (WT 11.08%, Il40-/- 0.22%; **). 
There were also significant changes in the phylum Proteobacteria, where the genus 
Desulfovibrio was not detected in three Il40-/- mice (WT 0.62%, Il40-/- 0.01%; **), while the 
genus Bilophila was detected in all Il40-/- mice, but not in WT mice (WT 0%, Il40-/- 0.06%; 
**). These data strongly suggest that the lower levels of IgA in the gut of Il40-/- mice affect 
the diversity of their microbiome. 
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Figure 2.11. The microbiome of Il40-/- mouse is altered. (a) Alpha diversity of fecal 
samples from WT or IL40-/- mice. (b) Beta diversity of WT or IL40-/- mice. (c) Relative 
abundances in percentage of different microbial Phyla represented in WT or IL40-/- mice. 
n=5 per group (*p<0.05). 
 
Human IL-40 is expressed by activated human B cells and human B cell 
lymphomas.  
Human peripheral blood B cells activated with anti-CD40 Ab plus IL-4 for 24 hours, 
showed strong up-regulation of expression of human C17orf99/Il40 (Figure 2.12a). We 
also tested various human non-Hodgkin B cell lymphoma lines (42) for IL-40 expression 
by qRT-PCR and observed that several of them (OCI-Ly1, HL-2 and Val) produce IL-40 
constitutively (Figure 2.12b). The latter observation suggests that IL-40 may play a role 
in the pathogenesis of human lymphomas (43). Interestingly, the Il40+ lymphomas also 
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express the B cell activation antigen TSPAN33 (8), indicating that they exhibit an 
‘activated’ B cell phenotype (43). Taken together, these results indicate that C17orf99 
encodes a novel B cell-derived cytokine (interleukin 40) that has significant effects in the 
immune system. 
 
Figure 2.12. Human B cells produce IL-40. (a) qRT-PCR analysis of IL-40 expression in 
human resting and activated human B cells. Cells were activated for 24h with anti-CD40 
Ab + IL-4, representative of three independent experiments (Mean+/-SEM) (***p<0.0005). 
(b) IL-40 expression pattern in several human diffuse large B-cell lymphoma cell lines 
(qPCR) (representative experiment out of 3 shown). 
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2.3 DISCUSSION AND CONCLUSIONS 
We initially sought to identify novel immune system associated genes. To this end, we 
analyzed a comprehensive database of human gene expression (BIGE) for genes 
expressed by immune system-associated organs including tonsil, lymph nodes, spleen, 
thymus, bone marrow and fetal liver. This analysis yielded 35 poorly characterized genes 
predicted to encode either transmembrane or secreted proteins, many of which are 
completely uncharacterized and were only annotated in the genome through their 
chromosomal location.  For most of these, there is yet, no information linking them to the 
immune system. We have reported three of these genes: Isthmin 1, a large secreted 
protein originally described in the brain of Xenopus, but which in mammals is expressed 
by NK, NKT and Th17 cells (7), Tetraspanin 33 (TSPAN33), a membrane protein which 
represents a novel biomarker of activated B cells (8), and Meteorin-Like (METRNL/IL-
39)(44), a secreted protein related to a known neurotrophic growth factor (Meteorin) that 
is expressed by activated macrophages. In the present study, we focused on C17orf99, 
because it is predicted to encode a small secreted protein (~27 kDa) and is expressed by 
activated B cells, fetal liver and bone marrow. Further analyses indicate that the cellular 
source of mouse C17orf99 in the bone marrow is CD45- cells, which are enriched in 
stromal cells. This is not surprising since these cells are known to produce many cytokines 
(27)). Mouse C17orf99-producing cells in the bone marrow are further enriched in the 
lineage-CD45-CD51- bone marrow population (Figure 2.7c). Interestingly, CD45-CD51+ 
cells include stromal cell precursors that support the development of bone and cartilage, 
while CD45-CD51- cells include mature stromal cells that support hematopoiesis and 
lymphopoiesis (33). These observations strongly suggest that mouse C17orf99 is 
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produced by stromal cells that participate in lymphopoiesis. Along with this observation, 
we have observed reduced numbers of B220+ cells in the bone marrow of C17orf99-/- 
mice (Figure 2.7b), reflecting slightly reduced numbers of Pro and Pre-B cell precursors 
in the bone marrow (Figure 2.8). Taken together, these observations suggest that IL40 
plays a role in B cell development in the bone marrow. However, further studies are 
necessary to confirm this hypothesis. Conversely, we have not detected abnormalities in 
hematologic precursors in C17orf99-/- mice suggesting that C17orf99 is mainly linked to 
B cell development and function.  
Data from the BIGE database indicate that C17orf99 is expressed by human peripheral 
blood B cells activated with anti-CD40 and IL-4 (Figure 2.1a). We confirmed the latter 
observation with the murine B cell lymphoma A20-2J (Figure 2.4a) and mouse spleen B 
cells (Figure 2B). The fact that C17orf99 encodes a small secreted protein (~27kDa) and 
that its expression is inducible in B cells upon activation, strongly suggests that C17orf99 
encodes a novel cytokine. Recently, a new member of the IL-12 family has been identified 
and named IL-39(44, 45). We therefore have named the product of C17orf99 Interleukin 
40 (IL-40) since that is the next number in the interleukin sequence (11). 
Cytokines are very important molecules in the immune system.  It is therefore relevant to 
ask why C17orf99/Il40 has not yet been identified as a cytokine. Several factors may 
account for this. These include: a) It is expressed by a limited number of tissues (bone 
marrow and fetal liver); b) It does not belong to any recognized cytokine family (structural 
features would have facilitated its identification) and c) Its main producers in the periphery 
(B cells) are not known to be prolific cytokine producers (46). On this last point, we should 
note that recently, some B cell subsets have achieved notoriety precisely through their 
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ability to differentiate into cytokine producers. An excellent example are the B10 
regulatory cells (which produce IL-10) and are believed to be involved in autoimmunity 
(47). On the other hand, C17orf99 has been recognized to encode a secreted protein 
(26), and Tang et al (25) included it in a library of knockout mice that encode 
transmembrane or secreted proteins.  
B cells require several signals for optimal expression of IL-40. One of these involves the 
B cell receptor (represented by the anti-IgM stimulus), and anti-CD40 Ab, or CD40L. The 
second signal is represented by cytokines like IL-4, which induces B cell activation and 
proliferation. Interestingly, among several cytokines tested, we found that TGF-β 
potentiates the expression of Il40 by activated B cells (Figure 2.4b). The ability of 
cytokines like IL-4 and TGF-β to potentiate IL-40 production by B cells suggests that 
optimal IL-40 expression by B cells may require a specific differentiation mechanism (46) 
to achieve optimal production. These “B40” cells could develop in vivo under certain 
conditions. In support of this, other B cell subsets have been described that require a 
specific differentiation mechanism in order to become strong cytokine producers. For 
example, IL21 is required for B10 cells to develop in vitro (28). Similarly, an IL-40-
producing subset of cells (B40 cells) may be associated with specific immune responses 
or human diseases.    
As represented in a phylogram (Figure 2.1d), C17orf99 is only present in mammalian 
genomes. This observation led us to hypothesize that IL-40 may have a mammalian-
specific function. Importantly, IL-40 expression is induced upon the onset of lactation, and 
it correlates with the expression of IgA in the milk.  Further support for a role in IgA 
responses comes from the phenotype of an Il40-/- mouse which shows a reduction in size 
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and numbers of Peyer’s patches, in IgA+ B cells, in IgA levels, as well as significant 
differences in its microbiota. The reduction in serum immunoglobulins is reminiscent of 
the phenotype of the B cell activating factor BAFF-/- mouse (48), which exhibits a severe 
reduction in serum immunoglobulins; however, unlike the Il40-/- mouse, the BAFF-/- mouse 
only exhibits a moderate reduction in IgA levels. Ablation of another TNF family member, 
APRIL, also resulted in reduction of IgA serum levels (49). The inability of the Il40-/- mouse 
to produce normal levels of IgA suggests that the ablation of Il40 may be altering a 
mechanism that specifically affects this B cell subpopulation. Furthermore, the changes 
observed in the microbiome of the Il40-/- mouse are likely a consequence of the altered 
IgA production in mucosal tissues (50). Conversely, the number of lymphocytes in the 
Peyer’s Patches and other GALT is influenced by microbial colonization (51), reflecting 
common evolutionary mechanisms. Taken together, these observations suggest an 
important role for IL-40 in either the proliferation or differentiation of IgA-committed B 
cells.  
Another interesting IL-40-linked cytokine is TGF-β, which is also involved in IgA 
responses (52), and, as we show in Figure 2.4b, potentiates IL-40 production by B cells. 
This raised the possibility that abnormal production of TGF-β in the Il40-/- mouse could 
account for the lower IgA levels observed in this mouse. However, we have tested the 
capacity of activated T cells from Il40-/- mice to produce TGF-β and it appears normal.  
Activated human peripheral blood B cells also produce IL-40 (Figure 8a). Importantly, 
some human B cell lymphomas can produce IL-40 constitutively (Figure 2.12b). B cell 
ablation therapies (i.e. anti-CD-20 mAbs) have shown significant therapeutic benefit in 
several autoimmune diseases including multiple sclerosis (53), and rheumatoid arthritis 
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(54) . Yet, the mechanism(s) through which B cells participate in the pathology of these 
diseases remains undefined (46), although it is unlikely to be due to autoantibodies 
because the ablation of B cells (for example, using rituximab (55)) does not affect plasma 
cells or autoantibody titers. An emerging concept is that B cell derived cytokines (28, 47) 
may affect the development of autoimmunity. The latter observations suggest that IL-40, 
as a B cell-associated novel cytokine, is an excellent candidate to be involved in the 
pathology of human diseases, including autoimmune diseases (56) and lymphomas (57), 
where activated B40 cells may play an important role in their pathogenesis (46).  
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CHAPTER 3 
IL-40 and its potential role in disease
 102 
 
3.1 INTRODUCTION 
In Chapter 2 we observed the potential role of IL-40 in disease (Figure 2.12), we decided 
to further explore the role of IL-40 in disease. As discussed before, B cells are more than 
immunoglobulin-producing cells for the immune response. B cells also take part in the 
regulation of immune response, such as, antigen presentation and the regulation of 
cellular immunity through the secretion of cytokines (1, 2). The potential of B cells in 
immune response regulation was proven by the significant effects observed upon B cell 
depletion using the anti-CD20 antibody rituximab (2). It has been observed that 
differentiated plasma cells (which do not express CD20) can resist B cell depletion 
targeting CD20, thus the autoantibody production does not decline after treatment. 
However, when targeting CD19 the specific IgM and IgG1 responses can be nullified; in 
both cases the immune response of T cells is affected by the depletion of B cells (3-8). 
The patient’s reaction to depletion therapy cannot be predicted, since depending on the 
autoimmune disease, it can either aggravate or alleviate the disease (6, 9, 10). This wide 
effect caused by B cell depletion can be explained by the positive feedback interaction 
between T cells and B cells in the lymph nodes where B cells can present autoantigens 
to T cells which in turn “stimulate” B cells to produce specific autoantibodies and secrete 
pro-inflammatory cytokines (11, 12). Recent studies have shown that the ablation of IL-
6-producing B cells ameliorate the disease in experimental encephalomyelitis (EAE), a 
murine model of multiple sclerosis (MS)(11). Barr and colleagues found that B cells are a 
major source of IL-6 in mice and that IL-6-producing B cell supernatant have an enhanced 
proliferative effect on T cells in vitro (11). The accumulating evidence over the last years 
suggests that B cells are more than an immunoglobulin-producing machine. The capacity 
of B cells to participate in antigen presentation, cytokine production, as well as regulatory 
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functions (2), strongly suggests that they represent important targets of research for the 
control and diagnosis of autoimmune disease.  
The ability of B cells to produce cytokines has been known since the early 1970’s. B cells 
can secrete proinflammatory cytokines, growth factors, and immunosuppressive 
cytokines at similar levels of other cytokine-producing cells (1, 13). Cytokines produced 
by B cells are important, especially to regulate the interaction between B cells and 
regulatory T cells (Tregs), in some cases, they act as direct activators of T cells or as 
indirect activators through macrophages. In addition, they can regulate macrophage 
activity during pathogenesis (14, 15). The role of Tregs in the regulation of immune 
system is essential, nevertheless the inability to produce Tregs in vitro with full regulating 
activity in vivo (16) makes the study of B cell/-Treg interactions an important case study 
to explain how B cells-cytokine production and repertoire help in the development of 
pathogenic T cells and Tregs in autoimmune pathogenesis. This notion is further 
supported by the multiple reports of altered cytokine patterns in many autoimmune 
diseases (1).  
In 1974 an immune suppressive role for B cells was first identified (17). Almost 30 years 
later the mechanism of action of regulatory B cells (Bregs) was discovered to be the ability 
to produce IL-10 in a murine model of chronic intestinal inflammation (18). IL-10 is a 
known regulatory cytokine first discovered in populations of T helper cells (Th) with the 
ability to suppress the production of proinflammatory cytokines, such as, interferon 
gamma, IL-2, and tumor necrosis factor (19) and its ability to co-stimulate the proliferation 
of thymocytes (20). In fact, it was originally recognized that it was a product of certain B 
cell lymphomas (21, 22).It is better known for its ability to inhibit the production of certain 
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cytokines, especially IFN, although its mechanism of action was mapped to its ability to 
inhibit macrophages (20). 
Nevertheless, we now know that IL-10 exerts its activity not only in the adaptive response, 
but in the innate immune system as well. The mechanism of action of IL-10 has been 
extensively reviewed in the context of autoimmune disease and is considered a master 
regulator of autoimmune response (23-26). IL-10 is capable of reducing T cell activation 
through the downregulation of MHC-II and co-stimulatory molecules, as well as 
suppressing antigen presentation by dendritic cells further reducing the activation of T 
cells and B cells (24). In the case of MS B cells, they are known to amplify the pathogenic 
autoimmune response, producing high levels of pro-inflammatory cytokines while 
producing low levels IL-10 (27). Interestingly, this reduced level of IL-10 is shared by other 
autoimmune diseases such as colitis and arthritis (18, 28). It has also been found that 
during relapses in patients with MS, triggered by infection through the activation of TLRs, 
the B cell populations present an abnormal cytokine response characterized by increased 
lymphotoxin to IL-10 ratios which can be reverted by B cell depletion (29). 
B cells also play an important role in the pathogenesis of RA, as indicated by the rate of 
success of B cell depletion treatment in RA patients (12). One of the mayor pathogenic 
agents of RA, the receptor activator of nuclear factor B ligand (RANKL), is highly 
expressed by B cells in patients with RA (30). RANKL expression is induced by 
proinflammatory cytokines (TNF, IL-6, IL-1) and the expression of RANKL drives bone 
destruction in RA (30, 31). In addition to RANKL, B cells in the synovial fluid of RA patients 
have been found to produce IL-6 and lymphotoxin beta (LTβ) which haven show to 
exacerbate inflammation of the joint tissue(32, 33).  
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Atherosclerosis is a disease where autoimmunity plays a role in the establishment of the 
disease. Early chronic inflammation sets the stage for atherosclerosis development and 
both the adaptive and the innate immune response play a role in its pathogenesis (34). B 
cells are known to infiltrate to the atherosclerotic lesions and form follicle-like structures 
within the lesion, comprised of populations of follicular dendritic cells, macrophages and 
CD3+ T cells (35). As pointed by Hamze and collaborators (2013), B cells can have 
contradictory roles in atherosclerosis. It has been observed that the treatment of 
atherosclerosis prone mice (apoE-/- model) by B cell transfer has a protective effect (36). 
However, it has been found that while ablation of CD20+ B cells ameliorates the disease 
progression in mice, the selective transfer of B2 B cells exacerbates the disease by 
>300% (37). These data hints at the possible regulatory role and that B cells are carrying 
and effector function regardless of antibody production.  Indeed, it was later reported that 
mature B2 B cells express proinflammatory cytokines (IL-6, GM-CSF, and TNF) and can 
induce polarization of other effector immune cells (1). 
B cells are also involved in the development of Diabetes, a metabolic disease. Obesity-
provoked glucose intolerance and insulin resistance are characterized by the presence 
of proinflammatory T cells and macrophages in visceral adipose tissue (VAT). B cells are 
known to infiltrate in diet-induced obese (DIO) mice with insulin resistance, but mice 
lacking B cells are protected against insulin resistance (38). Winer et al showed that those 
VAT infiltrating B cells were producing elevated quantities of IgG2 antibodies and 
promoting pro-inflammatory cytokine production by T cells. However, it has also been 
found that patients with T2D produce lower levels of IL-10 and higher levels of CXCL8. 
These patients also present a slightly elevated presence of TLR in the membrane of B 
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cells, which could be one of the causes of abnormal levels of cytokines (39). In the case 
of TD1, B cells support the proliferation and survival of pathogenic CD8+ T cells and in 
the absence of B cells, the cytotoxic T cells were found apoptotic and unable to survive 
(40). 
During infection B cells can respond to PAMPs and release cytokines and antibodies to 
combat infection. B cells express different TLRs and can be upregulated in response to 
BCR crosslinking (41, 42). Although expression levels and functions vary between mouse 
and humans, both human and murine B cells engaging them lead to CSR, proliferation, 
migration and differentiation (41, 43). This process is especially important in mucosal 
tissues since it is constantly colonized by microorganisms. It has been found that mucosal 
B cells in contact with Polyinosinic:polycytidylic acid (Poly I:C), a synthetic analog to 
dsRNA, can induce CSR to IgA in the presence of B cell-activating factor of the TNF 
family (BAFF)(44). B cells arrive to the gut and receive cues from the environment in 
mucosal-associated lymphoid mucosal tissue (MALT) which includes PPs and 
mesenteric lymph nodes (MLNs). In mucosal tissues IgA is the most secreted class of 
immunoglobulin (45). IgA secretion does not lead to inflammation and contributes to the 
homeostasis of the mucosal epithelium, with a pivotal role in gut homeostasis (46). There 
are two types of IgA secreted in the gut, high affinity and low affinity IgA. The high affinity 
is induced by pathogen’s PAMPs and toxins and is T cell help dependent (carried out in 
GALTs); whereas low affinity IgA is induced by commensal pathogens is produced 
independent of T cell help from B cells in the intestinal lumen (47). Low affinity IgA is 
important in the structuration and control of the commensal microbiota, nevertheless both 
Low and High affinity IgA have been shown to have small roles in both aspects of mucosal 
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defense and homeostasis (46). Recently it was reported by the Flavell lab that colitogenic 
bacteria is highly coated by IgA in patients with IBD (48). The IgA coating the colitogenic 
bacteria is believed to be high affinity IgA. This interplay between the control infection and 
the control of commensal bacteria remarks the complex roles that B cells can play in 
pathogenesis.   
Understanding the role B cells in the pathogenesis of a given disease is a precondition 
for the development of effective treatments. Since the depletion of B cells can often have 
contradictory outcomes it is important to study how B cells are contributing to 
pathogenesis. Is it through the production of autoantibodies or through an effector 
pathway mediated by cytokine production? IL-40 could influence disease, through any of 
these mechanisms. Therefore, we decided to test the influence of IL-40 using the Il40-/- 
mouse as a tool. We sought to test Il40-/- mice in murine models of disease where B cells 
have significant role; microbiome-dependent Salmonella gut infection (IgA can also play 
a role), EAE for MS-like disease and FAS receptor mutant (Faslpr/lpr) mice which develop 
autoimmune lymphoproliferative disease and are widely considered an SLE-like model. 
3.2 MATERIALS AND METHODS 
Bacterial Strains and Growth Conditions. IR715 is a fully virulent, nalidixic acid 
resistant derivative of Salmonella enterica serovar Typhimurium wild-type isolate ATCC 
14028. ΔaroA is a mutant strain of S. enterica serovar Typhimurium lacking aroA protein 
involved in the synthesis of aromatic amino acids. The lack of aroA renders S. enterica 
Thyphimurium ΔaroA strain highly attenuated (49). All strains were grown aerobically at 
37°C in Luria-Bertani broth supplemented with nalidixic acid. 
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Mouse oral immunization with Salmonella. Il40-/- mice or WT littermates were 
immunized by oral inoculation with 1x109 Colony Forming Units (CFUs) of S. enterica 
serovar Typhimurium ΔaroA. Mice were boosted 7 days later with 1x109 CFUs of the 
same Salmonella strain. 
Challenge with full virulent Salmonella. Il40-/- mice or WT littermates were challenged 
with the full virulent S. enterica serovar Typhimurium strain IR715 15 days post 
immunization. To do so, mice were treated with streptomycin (1g per kg of mouse weight 
in sterile water) intragastrically 1 day prior to infection and the following day mice were 
infected orally with full virulent S. Typhimurium (1× 109 cfu/mouse). Fecal pellets were 
collected at 24, 48 and 72 hours post-infection to monitor bacterial burden. Mice were 
euthanized 96 hours after challenge, and spleen, mesenteric lymph nodes, terminal 
ileum, colon contents and fecal pellets were collected to determine bacterial burden. 
Serial 10-fold dilutions were plated for enumerating bacterial CFUs on agar plates 
containing nalidixic acid.  
Measurement of total IgA in feces. Fresh fecal samples were collected before and 
after immunization, and 96 hours post challenge. Fecal pellets were weighed and 
resuspended in 1 mL of sterile PBS containing a protease cocktail inhibitor (Roche) 
and incubated at room temperature shaking for 30 minutes. Samples were centrifuged 
at 7,200x g for 10 minutes and the supernatants were collected to measure total IgA 
using an ELISA kit (Bio-Legend). Data was normalized using the weight of the sample. 
Induction of EAE and clinical scoring. Age-matched (8 weeks) male C57BL/6 mice and 
Il40-/- were immunized by subcutaneous injections with 100l of emulsion containing 100g pf 
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myelin oligodendrocyte glycoprotein MOG35-55 (MEVGWYRSPFSRVVHLYRNGK-COOH; 
Thermo Fisher) in PBS, with complete Freund’s adjuvant containing 200g Mycobacterium 
tuberculosis H37Ra (DIFCO Laboratories). Clinical evaluation was performed every 2 days 
double-blind and based on the following scoring system; 0, asymptomatic; 0.5, ruffled fur; 1, 
flaccid tail; 2, hind limb paresis; 2.5, partial hind limb paralysis; 3, hind limb paralysis; 4, hind limb 
and forelimb paralysis; 5, moribund. Mice were sacrificed via inhalation of a lethal dose of 
isoflurane and cardiac perfusion with PBS was performed at defined time points post-transplant 
for tissue harvesting and analysis.  
Il40-/-Faslpr/lpr mouse generation. C57B/6J Faslpr/lpr males (carrying both alleles of Fas 
receptor lymphoproliferation=lpr autosomal recessive mutant) were purchased from 
Jackson Laboratory (Bar Harbor, Maine, USA) and crossbred with female Il40-/- mice 
(bred at our UCI’s mouse facilities). The double heterozygous F1 generation (Il40-
/+Faslpr/wt) were crossbred to obtain Il40-/-Faslpr/lpr mice. Mice were validated for Faslpr/lpr by 
genotyping using standard multiplex primer PCR with common primer oIMR1678 (5’ GTA 
AAT AAT TGT GCT TCG TCA G 3’), mutant primer oIMR1679 (5’ TAG AAA GGT GCA 
CGG GTG TG 3’) and WT primer oIMR1680 (5’ CAA ATC TAG GCA TTA ACA GTG 3’). 
The amplicons were analyzed by electrophoresis. Mutant amplicon size is 217 base pair 
(bp); Heterozygote is 179 and 217 bp and WT is 179 bp. Il40-/- mutation was genotyped 
as described in chapter 2. 
3.3 RESULTS 
IL-40 plays a role in the modulation of commensal induced IgA in the gut 
The Il40-/- mice exhibit a shift in the taxonomical composition of the gut microbiota (Figure 
2.11) and reduction of IgA production in the intestinal mucosa under homeostatic 
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conditions (Figure 2.9). Both, the microbiota and IgA confer protection to the host against 
enteric pathogens (50), therefore we tested whether IL-40 plays a role in the host defense 
using the enteric pathogen Salmonella.  
In homeostatic conditions, the gut microbiota provides effective colonization resistance to 
Salmonella (50). We infected WT mice and Il40-/- littermates with Salmonella enterica 
serovar Typhimurium infection and mice were euthanized at 96 hours post-infection to 
determine the bacterial burden in the feces, cecum content, mesenteric lymph nodes and 
spleen. We did not find any difference in the bacterial burden between WT and Il40-/- mice 
(Figure 3.1 white dots). These data indicate that the changes of the gut microbiota in 
absence of IL-40 do not have an impact in colonization resistance during the acute 
infection with Salmonella. Because Il40-/- mice also have a defect on IgA production in 
the intestinal mucosa, we evaluated whether the absence of IL-40 might have an impact 
on the induction of a secondary immune response against Salmonella. To this end we 
immunized WT and Il40-/- mice with an avirulent Salmonella strain (Salmonella ΔaroA) 
and 15 post-immunization we challenged the mice with the full virulent Salmonella strain 
IR715. Immunized WT mice was protected against the challenge with full virulent 
Salmonella since bacterial burden was reduced in the gut, MLN and spleen. We found 
that immunized Il40-/- mice was also protected after challenge with full virulent Salmonella, 
we observed similar bacterial burden in WT and IL-40 deficient mice after immunization 
(Figure 3.1, black dots). These findings suggest that IL-40 does not participate in the 
induction of an adaptative immune response against the enteric pathogen Salmonella.  
However, when we measured the levels of IgA in the gut, during the primary infection and 
after the challenge with full virulent Salmonella in immunized mice, we found that IgA 
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levels are restored in IL-40 deficient mice upon acute infection (Figure 3.2). Remarkably, 
IgA levels are similar in WT and Il40-/- mice when were immunized and challenged with 
full virulent Salmonella (Figure 3.2).; this finding correlates with what we observe in terms 
of bacterial burden. These results suggest that IL-40 may play a role in the regulation of 
commensal induced IgA (low affinity IgA) as opposed to pathogen induced IgA (high 
affinity IgA) secreted in the gut under pathogenic bacterial attacks. 
 
Figure 3.1. Bacterial burden of Salmonella after challenge. (a) Bacterial burden in WT 
and Il41-/- measured in fecal samples (FS) at 72 hours (h) post infection in logarithmic 
colony forming units (Log CFU) and normalized to fecal sample weight. Representative 
of two separate experiments. Bars represent mean, *p<0.05 and **p<0.01. (b) Bacterial 
burden in WT or Il40-/- spleen, mesenteric lymph nodes (MLN) and cecum content (CC). 
Representative of two separate experiments. Bars represent mean, **p<0.001. Each dot 
represents an individual mouse. 
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Figure 3.2. IgA normalizes after Salmonella challenge in Il40-/- mice. IgA levels were 
measured before and after immunization and/or challenge by ELISA. Representative of 
two separate experiments. Each dot represents an individual mouse. *p<0.05 and, 
**p<0.01, ***p<0.001. 
 
IL-40 in EAE 
Considering the role of B cells in MS and knowing that Il40-/- mice have reduced numbers 
of circulating mature B cells, we decided to test if IL-40 is important for the amelioration 
or exacerbation of EAE pathology. To test this, we immunized WT and Il40-/- mice with 
MOG35-55. On our first experiment we observed a significantly delayed onset of disease 
but no significant differences in disease severity (not shown). Surprisingly in a second 
experiment we found no significative difference between in EAE score or onset of the 
disease (Figure 3.3a) and no significant differences in the number of cells, other than B 
cells, in the draining cervical lymph nodes (cLN) and spleen at the peak of the disease 
(day 35) (Figure 3.3b and c). The fact that even with reduced numbers of B cells we did 
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not see any significant change in the clinical scores or in the onset of disease is vexing 
however we did notice that none of the individuals tested surpassed score 3 in the clinical 
score scale and thus we obtained a low overall average score per group. Taking these 
data together we can conclude that IL-40 does not play a role in EAE pathogenesis in the 
mouse immunized with MOG35-55. 
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Figure 3.3. IL-40 ablation does not play a role during EAE induced by MOG35-55 
immunization. (a) Clinical scores over time in days of WT and Il40-/- mice immunized with 
MOG35-55. (b) Total cell numbers in cervical lymph node (cLN) 35 days post 
immunization. (c) Total cell numbers in spleen 35 days post immunization. CD45+ cells 
(CD45+), conventional DCs (cDCs), Natural Killer (NK), plasmacytoid DCs (pDCs), CD8+ 
T cells (CD8+) and CD4+ T cells (CD4+). Bars represent +/- SEM, n= 5 mice per group, 
*p<0.05. 
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IL-40 role in SLE-like disease 
After observing the B cell deficiencies in Il40-/- mice and the importance of B cell effector 
function we decided to test whether IL-40 participates in the pathogenesis of 
lymphoproliferative autoimmune disease. First apoptosis antigen receptor (FAS) 
mutations lead to a series T cell and B cell homeostasis disruptions that leads to the 
secretion of autoreactive antibodies, lymphoproliferation of pathogenic T cells (CD4-CD8-
CD3+ T cells or DN T cells), pathogenic B cell activation and nephritis, all present during 
SLE pathogenesis (51). 
To test this out we sought to cross the Il40-/- mice with a FAS lymphoproliferation mutant 
mouse (C57B/6J Faslpr/lpr) to produce a double mutant cross (Il40-/-Faslpr/lpr). We sought 
to measure hallmarks of autoimmune disease such as the presence of anti dsDNA 
antibodies in serum and lymphoproliferation of DN T cells in lymph nodes and spleen 
characteristic of Faslpr/lpr mice strains (52). Nevertheless, we did not obtain Il40-/-Faslpr/lpr 
mice after crossing heterozygous mice for both genes (Figure 3.4). These results strongly 
suggest that the disruption of both genes results in an embryonic lethal phenotype.  
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Figure 3.4. Dihybrid crossbreeding of Il40-/+Faslpr/wt mice does not produce a double 
mutant. Punnet squares predicting allele combinations in a dihybrid Het/Het 
crossbreeding event (Il40-/+Faslpr/wt x Il40-/+Faslpr/wt) depicted as AaBb x AaBb. The table 
shows the theorical predicted frequencies and the expected probabilities of obtaining the 
multiple genotypes. The litter genotype and Litter % column represent the number 
obtained after crossbreeding. 
 
3.3 DISCUSSION AND CONCLUSIONS 
Non-typhoidal Salmonella (NTS) infections, including S. enterica serovar Typhimurium, 
account for a significant share of food-borne around the world (53). In the typical cases 
of NTS diarrhea, the pathogen begins to grow in the gut and disease symptoms manifest 
eight to 24h after consumption of contaminated food or water. Elimination of S. 
Typhimurium from the gut lumen involves two mechanisms. The first one acts during 
acute disease and is mediated by inflammatory response and the second involves the 
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formation of a protective IgA antibody response. The high-affinity IgA is secreted into the 
gut lumen, where it binds to the pathogen surface and blocks further pathogen access to 
the mucosal surface (54) and/or accelerates pathogen clearance from the gut lumen (50). 
Protection mediated by IgA occurs in an O-antigen-specific fashion a carbohydrate 
epitope exposed in the surface of Salmonella (50, 55). Also, it should be mentioned that 
the IgA-mediated S. Typhimurium removal is enhanced by the microbiota (50). The 
immune response against Salmonella in humans is driven by the adaptive immune 
response, mainly Th1, Th17 and B cells (56). B cells are dispensable for the for primary 
infections with Salmonella but are indispensable for subsequent challenges (57). In fact, 
B cell deficient mouse are susceptible to Salmonella infection due to impaired Th1 
responses, underscoring the importance that the effector role that B cells may play in 
immunity against Salmonella (57). The main humoral response in the gut is represented 
by IgA. B cells (and plasma cells) in the gut secrete large amounts of IgA. Hybridomas 
engrafted in mice producing a clone of anti-O antigen IgA (Sal4) can prevent Salmonella 
infections in vivo (55, 58). IgA also is one the main regulators of normal microbiota in the 
gut which is important to control infection (59). We hypothesized that IL-40 could play a 
role in the during Salmonella infection due to the IgA deficiency (Figure 2.6), the disrupted 
microbiome (Figure 2.11) and B cell deficiency (Figure 2.9) in the Il40-/- mice, since these 
three factors can play a role during Salmonella infections. Interestingly, we did not see 
any difference in disease severity, clearance or bacterial burden (Figure 3.1), but we did 
observe a change in the secretion of IgA after challenge in the Il40-/- mice after challenge 
with virulent Salmonella which could explain why we do not see any difference in disease 
severity (Figure 3.2). Nevertheless, we do not know what type of IgA is being secreted 
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after challenge, but we hypothesize that high affinity IgA likely represents the type 
increased after challenge while low affinity IgA is the one decreased constitutively in the 
Il40-/- mice. This hypothesis is supported by fact that immunization did protect mice 
against colonization (Figure 3.1a). This model therefore suggests that IL-40 plays a role 
in the induction of low affinity IgA but not in high affinity. 
B cells have a long history in EAE pathogenesis (60). In fact, a novel anti-CD20 
monoclonal antibody has recently been approved for treatment of human multiple 
sclerosis (60). Autoreactive antibodies targeting myelin and axon structures are a 
hallmark of EAE and MS pathology. Effector B cells act as APCs to autoreactive T cells 
and coordinate the formation of ectopic lymphoid organs that promote pathogenesis in 
EAE (23, 61, 62). Additionally, mice lacking B cells have shown to have increased 
variability in disease onset, clinical scores and impaired recovery in EAE (63). The 
generalized B cell deficiency in the Il40-/- made hypothesize for a role of IL-40 in EAE. 
Notwithstanding, Il41-/- mice did not behave differently to WT mice in any of the 
parameters measured despite significantly reduced B cell numbers in cLN and spleen 
(Figure 3.3). We believe that the immunogen selected for the induction of EAE could be 
a factor. MOG35-55 peptide induces EAE independently of B cell effector activity, 
whereas full length oligodendrocyte glycoprotein (MOG) is unable to induce pathogenesis 
in the absence of mature B cells (64). Unique autoantibodies in plasma of mice immunized 
against MOG but not MOG35-55 have been found (65). Thus, we cannot eliminate the 
possibility that IL-40 may be playing a role in the development of B cell responses in the 
presence of MOG protein. Taken these data together, we can conclude that IL-40 does 
not play a role in EAE pathogenesis induced by MOG35-55 peptide, but there is still the 
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possibility that it may play a role when the (alternate) peptide would be used. Future 
studies should aim to answer this question. 
Finally, we wanted to explore the role of IL-40 in Fas lymphoproliferation allele (Faslpr/lpr) 
mice, a murine model that recapitulates some of the SLE and autoimmune 
lymphoproliferative syndrome (ALPS) hallmarks (66). Faslpr/lpr mice have a mutant allele 
Similar to MS the presence of autoantibodies is a hallmark of the pathogenesis in SLE 
and in Faslpr/lpr mice (67, 68). Fas induces apoptosis of autoreactive T cells and B cells 
through the binding of its ligand (FasL) (69-71). In B cell biology, Fas ligand expressed in 
CD4+ T cells induces apoptosis of germinal center B cells undergoing selection for non-
reactive or autoreactive BCRs (69, 72). Disruption of the Fas/FasL interaction enables 
the proliferation of autoreactive T cells, double negative T cells (CD4- CD8- CD3+ T cells; 
DN T cells) and autoreactive B cells (69, 73). Due to the B cell defects present in the Il40-
/- mice and previous reports of B cell deficient mice being protected from autoimmune 
disease (74), we decided to cross our Il40-/- mice (C57BL/6J background) with a 
C57BL/6J Faslpr/lpr mice to determine the role of IL-40 in autoimmune lymphoproliferative 
disease. Nevertheless, we were unable to obtain a double mutant (Il40-/-Faslpr/lpr) mice 
after crossing Il40-/+Faslpr with Il40-/+Faslpr/wt individuals. The chromosomic location of the 
Fas allele and the Il40 allele did not interfere with the crossing (chromosome 19 and 
chromosome 11 respectively). None of the pups obtained (n=48) were double negative 
suggesting that the combination of mutant alleles are likely embryonic lethal. We 
hypothesize that the lack of Il40-/-Faslpr/lpr after heterozygous crossing could be due to an 
unknown role of IL-40 during hematopoiesis in fetal liver, were IL-40 is highly expressed 
(Figure 2.1a) while FAS plays a role in the development of HCSs (75). We do not yet 
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know what functions IL-40 could be playing in early hematopoiesis in the fetal liver, but 
the generalized B cell deficiency and the role of other cytokines (76) in hematopoiesis 
suggests that IL-40 could be important in the fetal liver. Furthermore, FAS is barely 
expressed by B cells in the periphery and the BM, but its expression is strongly 
upregulated in the presence of CD40 ligand (CD40L) (77). The balance of CD40/CD40L 
and Fas/FasL is necessary to shutdown T cell-dependent B cell responses; CD4+ T cell 
expressed CD40L inhibits apoptosis mediated by Fas/FasL as inflammation winds down 
expression of CD40L by CD4+ T cells diminishes inducing apoptosis on B cells highly 
expressing Fas (78). Interestingly, in the absence of T cell help, B cells can go into CSR 
and develop unchecked high affinity antibodies which could be autoreactive, the deletion 
of these cells is also mediated by Fas/FasL and thus Fas is an important mechanism of 
peripheral tolerance for B cells (79). These studies indicate the importance of Fas in the 
regulation of B cell lymphopoiesis, but Fas deficiencies can alter hematopoiesis since 
earlier stages, leading to a uncontrolled migration and proliferation of immature 
hematopoietic cells in the fetal liver and BM in adult mice with the lpr phenotype (80)This 
suggest that the IL-40 could have a major role in the control of hematopoiesis in the fetal 
liver and bone marrow that in combination with the defects created by the lpr phenotype 
make the mutations embryonic lethal. Further studies on the role of IL-40 in 
hematopoiesis in the fetal liver are necessary to confirm this. 
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CHAPTER 4 
 
Summary and General Conclusions
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4.1 SUMMARY AND FUTURE DIRECTIONS 
Discovery, mammalian functions, IgA secretion and GALT tissue homeostasis  
Interleukin 40 is the latest cytokine to be discovered (1). The discovery of IL-40 followed 
a different approach than other recently discovered cytokines. The gene encoding IL-40 
is annotated in the human genome as C17orf99 and it is mainly expressed in fetal liver, 
bone marrow and activated B cells. It encodes a small secreted protein (27kDa) of 265 
amino acids including a 20 amino acid signal peptide. We became interested in this gene 
while screening the Body Index of Gene Expression (BIGE) database (2) for 
uncharacterized genes related to the immune system. C17orf99 was identified as a gene 
of interest because of its expression pattern indicated that it was expressed in certain 
immune system organs (fetal liver, bone marrow), and the presence of a signal peptide 
predicted that it encoded a small secreted protein. It is not structurally related to any other 
cytokine family suggesting that it has unique evolutionary history. An estimated 10% of 
the human genome encodes secreted proteins. This human ‘secretome’ is very important 
because it contains many proteins that regulate a variety of physiological processes. In 
the case of the immune system, cytokines are pivotal molecules that regulate the 
development of cells of the immune system as well as development of immune 
responses. Furthermore, C17orf99 had been identified as a potential gene of interest on 
a wide screen of uncharacterized secreted genes (3). Bioinformatics analyses revealed 
that C17orf99 gene orthologs are only present in mammals, leading us to hypothesize 
that the function of C17orf99 should be related to a mammalian-specific immune function. 
That hypothesis proved correct when we measured immunoglobulin (Ig) levels in the milk 
of lactating Il40-/- mice. There was a significant decrease in the concentration of IgA in the 
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milk of Il40-/- mice and we also found that IL-40 expression is normally induced in the 
mammary gland prior to the onset of IgA production. In fact, we found a general IgA 
deficiency in Il40-/- mice (not only in the mammary gland). Interestingly, the gut of these 
mice is affected by the absence of IL-40, since we found a lower number (and smaller 
size) of Peyer’s patches (PPs) which could be explained by a significant decrease in the 
number of IgA+ B cells in the PPs as a well as a dysregulated microbiota.  
Salmonella infection  
The immunization experiments with Salmonella shed light on the potential mechanism 
that IL-40 carries in the gut. The first experiment performed was in an acute model of 
Salmonella infection that involves pretreatment with antibiotics to thin out the microbiome 
which allows for a severe gut colonization. In this model, IgA is not involved because the 
infection kills the mice very quickly (less than 1 week). In our experience, other knockout 
mice are highly susceptible, namely CCL28-/- mice (data not published), indicating that 
CCL28 is important in recruiting immune cells to the gut that are required to resist 
Salmonella in this model. In contrast, the Il40-/- mouse is resistant to Salmonella in this 
model indicating that IL-40 is not involved in recruiting the cells that mediate the 
resistance to Salmonella during acute infection. 
However, in another infection model that involves previous immunization, infection with 
virulent Salmonella (R715 strain) induced an increase of IgA in the gut of Il40-/- mice 
rescuing the reduced IgA phenotype observed in uninfected Il40-/- mice. This is an 
interesting observation, which suggests that IL-40 is important in maintaining the 
homeostasis of IgA responses, however, during active immunization IL-40 does not seem 
to participate in IgA responses. This indicates that it is possible that the mechanism of 
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production of homeostatic (low affinity) vs ‘immunizing’ (high affinity) IgA are different. To 
test this hypothesis, it is necessary to study the characteristics of IgA found in the gut of 
Il40-/- mice during infection and compare it to ‘homeostatic’ IgA. To further confirm this 
observations, it would be interesting to challenge Il40-/- mice with other gut pathogens. 
One candidate is Citrobacter rodentium, whose colonization depends on effector B cell 
function but not on IgA secretion (4). C. rodentia infection would help us determine two 
things; 1) whether the IgA secretion can be rescued by inflammation generated by 
another gut pathogen and 2) whether the altered GALT phenotype observed in Il40-/- mice 
increases the susceptibility to C. rodentia infection. Another good candidate is the 
protozoan Giardia muris whose colonization control is dependent on anti-Giardia IgA 
secretion (5). The importance of IgA in this model was observed when mice deprived of 
CD4+ T cells were unable to produce IgA to neutralize G. muris and, thus clearance of 
infection was impaired (6). By infecting Il40-/- mice with G muris we can infer the type of 
IgA being secreted, if we observe the same IgA secretion rescue observed with 
Salmonella and a normal clearance of G. muris would confirm that highly specific IgA is 
not controlled by IL-40. The easiest and more direct approach would be to perform IgA-
SEQ on the IgA secreted after exposure to Salmonella and compare it against naturally 
secreted IgA of uninfected Il40-/- mice. IgA-SEQ is a technique developed by Palm and 
collaborators (7) to sort bacteria based on the level of IgA coating on colonic bacteria (low 
to high level coating) using FACS. Fecal pellets are homogenized and stained with anti-
IgA antibody and sorted by FACS. Using this technique would also allow us to sort 
bacteria into different groups (depending on the IgA coating level) and perform rRNA 
sequencing to identify the bacteria being coated. By doing this we can compare 
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uninfected and infected Il40-/- bacterial populations based on their IgA coating allowing us 
to infer what kind of IgA is being increased after Salmonella infection. 
B cell development 
The IgA deficiency observed in the Il40-/- mice indicates that IL-40 is required for normal 
B cell function in the periphery. Thus, we decided to explore a possible function of IL-40 
in the BM, where B cells originate. We hypothesized that B cell development in the BM is 
impaired in Il40-/- mice. We first observed that mice have reduced numbers of mature B 
cells as well as of Pre-B cells in the bone marrow. Furthermore, the cells producing IL-40 
in the bone marrow are stromal cells, probably a subtype involved in lymphopoiesis. 
Following these results, we wanted to know whether B cells in the periphery were also 
affected in the Il40-/- mice. In fact, all B cell populations (transitional, follicular, and 
marginal zone) in the spleen were significantly reduced in Il40-/- when compared to WT 
mice, confirming that Il-40 plays a role in B cell maturation in the bone marrow and in the 
periphery. We do not know the exact mechanism that IL-40 is playing in the development 
of B cells, but it is remarkable that we see its effects in the BM and in the periphery. A 
good way to approach the role of IL-40 in this regard would be to generate chimeric mice 
(8). By transplanting Il40-/- BM cells to a WT mouse we can assess if B cell derived IL-40 
versus stromal derived IL-40 is important for B cell maturation in the BM and in the 
periphery. After 4-6 weeks post-transplant we could screen B cell populations in the BM 
and the spleen to determine if B cells remain affected in the periphery. If they remain 
affected that would mean that B cell derived IL-40 (or from another source) is needed for 
normal B cell maturation. A chimeric mouse would also allow us to observe whether GALT 
deficiencies and IgA general deficiency is dependent on B cell derived IL-40 or whether 
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there are other cell types that can produce IL-40 that is required for IgA secretion. Another 
subset of B cell biology that remains unexplored is the development of IgA+ plasma cells, 
it is possible that IL-40 is also important for the maturation or proliferation of IgA secreting 
cells. Measuring the presence of plasma cells and LPCs in the bone marrow and in the 
periphery would open another area of research for IL-40  
B40 cells 
We found that IL-40 can be produced by spleen B cells upon activation with anti-IgM, anti-
CD40 and IL-4 but that their ability to produce IL-40 increases significantly if the B cells 
are polarized in vitro with TGF-β. Therefore, TGF-β is necessary to have increased 
expression of IL-40 by activated B cells and is also necessary for IgA class switching in 
naïve B cells (9). In analogy to the IL-10 producing B cells I have previously discussed, 
we have named this TGF-β polarized, IL-40 expressing B cells, “B40 cells”. We 
hypothesize that B40 cells are present in tissues where IgA response develop. This raised 
a very important question, namely, are B10 cells the same as B40 cells? To clarify this 
issue, we sought to rule out the possibility of Breg/B10 cells were also producing IL-40. 
To this end, we differentiated B cells in vitro under conditions that favor B10 polarization 
using IL-21, the cytokine that drives B10 cell polarization and IL-10 upregulation (10). In 
parallel, we differentiated B cells to the B40 lineage and finally tested both B10 and B40 
polarized cells for IL-10 and IL-40 production. We found that IL-21 as described induces 
B10 cells as judged by their capacity to produce IL-10, while TGF induces B40 cells 
which lose their capacity to make IL-10 as well. These observations confirm that B40 cells 
are indeed a novel polarization stage of B cells that likely have important clinical 
implications.  
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There are two B cell lineages that can be polarized into effector cells, B1 cells and B2 
cells, both present in the spleen (11). B1 cells (also called innate-like B cells) are 
responsible for most of the secretion of natural (low affinity) IgM and IgA in a T cell 
independent fashion (12, 13). B1 cells are present in large numbers in the pleural and 
peritoneal cavities, as well as mucosal tissues but low overall in lymphoid tissues (12). 
The B2 B cell lineage represents most of the B cells found on the lymphoid tissues and 
are responsible for T cell dependent high affinity antibody production, although the MZ B 
cell subset can produce low affinity IgM and IgA independently of T cells (13). Both 
lineages are able to turn into effector Bregs cells given the right stimuli (11). For this 
reason, we tested B cells from the spleen which houses a mix of different subsets of B1 
and B2 cells for our polarization studies, but each B1 and B2 subset has specific 
functions. Thus, sorting these cells and stimulating specific subsets of B cells would tell 
us which B cell subsets are able to secrete IL-40 or if all of them can do it, helping us 
pinpoint the specific niches were IL-40 is needed for B cell development and IgA 
production. Other cells that can be a potential source of IL-40 are plasma cells, plasma 
cells are known to be cytokine producers although cytokine repertoire in plasma cells is 
limited, they are known to secrete cytokines that increase antibody production, such as 
TGF-β and IL-10 (14, 15). Furthermore, identifying specific populations that produce IL-
40 could help us discover subsets that could express the unknown IL-40 receptor.  
Finding the receptor would give important information about IL-40’s mechanism. We 
already have taken steps towards this goal using RNA sequencing. We stimulated human 
PBMCs with recombinant human IL-40. We observed that IL-40 is able to induce 
expression changes in B cells, T cells and Monocytes in combination with other 
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stimulatory signals (αCD40 + IL-4; αCD3 + αCD28 and LPS) or by itself (data not shown). 
Using the sequencing database, we aim to identify the membrane proteins that are 
upregulated in response to IL-40 to pinpoint the receptor. Alternatively, once an antibody 
is developed we could use immune precipitation followed by mass spectrometry to identify 
the possible receptor. We believe that since, IL-40 is likely an autocrine cytokine, B cells 
are good candidates to express the receptor. 
Clinical implications of IL-40 
We observed that some human B cell lymphoma cell lines (OCI-Ly1) constitutively 
express IL-40, suggesting a potential role for IL-40 in the pathogenesis of human B cell 
associated diseases. Many cytokines have been implicated in the prognosis of cancer. 
Elevated or decrease levels of cytokines can be markers for prognosis, for example high 
serum levels of IL-6 are associated with increased probability of metastasis in colorectal 
cancer (16) but in other cancers it correlates with better chances of survival (17). In the 
case of IL-40 we do not know whether IL-40 has direct role in the pathogenesis of B cell 
lymphomas. To study this, we propose to study the IL-40 expression in samples from 
Hodgkin’s and non-Hodgkin’s lymphoma patients and analyze whether IL-40 is 
associated with worse prognosis of the disease.  
In recent years, the importance of B cells in autoimmunity has become evident. Gene 
expression analyses have documented that activated B cells are present in autoimmune 
disease lesions like affected joint synovium in rheumatoid arthritis (18). Rituximab (an 
antibody against CD20, a marker of human B cells) has proven efficacious and has been 
approved by the FDA for treatment of several autoimmune diseases (19). Recently, 
another anti-CD20 antibody has been approved for multiple sclerosis (20). These 
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developments point to a pivotal role of B cells in autoimmunity. Given that the 
effectiveness of these treatments depends on their ability to eliminate B cells and not 
plasma cells (since the latter do not express CD20), their mechanism of action does not 
depend on the elimination of autoimmune antibodies, but rather, on the elimination of 
effector functions directly mediated by B cells. The most likely effector function therefore 
would be cytokine production. From this perspective, the identification of a novel B cell 
associated cytokine is a very interesting development (21). Importantly, we have also 
identified a novel effector B cell subset, the B40 cells, that are defined by their ability to 
express IL-40 following polarization with TGF-β. We hypothesize that in the future, we 
should learn more about the potential role of B40 cells in human disease. As B40 cells 
become better characterized at the molecular level, other biomarkers will be identified 
that may serve diagnostic purposes in either human autoimmune diseases where B cells 
are suspected to play a role as well as B cell lymphomas. As we have reviewed, activated 
effector B cells are now recognized as major players in the pathogenesis of several 
human autoimmune diseases and we therefore predict that IL-40, as a B cell associated 
cytokine, has the potential to be involved in the pathogenesis of some human diseases. 
We consider that gut autoimmune diseases where TGF-β is highly expressed may be 
likely to contain B40 cells (22). I am confident that in the next few years future studies will 
document associations of IL-40 with autoimmune mechanisms. 
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4.2 CONCLUSIONS 
 
This work summarizes the information we know about IL-40 to date. A previously uncharacterized 
gene (C17ORF99) encodes IL-40 which represents an important cytokine for B cell biology. 
Certainly, our research on IL-40 has left us with many more questions than answers, but we have 
a new field of research.  
In conclusion: 
• IL-40 is a novel cytokine produced by B cells upon activation  
• IL-40 is essential for efficient IgA production and normal GALT tissue development. 
o IL-40 likely plays a role in the production of high affinity IgA in the gut. 
• IL-40 participates in B cell ontogeny in the bone marrow and spleen and is 
produced by special cells in the bone marrow stroma. 
• In the periphery, IL-40 is likely produced by a B cell subset polarized by TGF-β, 
that we have designated B40 cells. 
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